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1. INTRODUCTION 
In the past decades angiography has been the keystone tool to assess coronary 
anatomy, leading to the development of largely applied revascularisation 
techniques such as coronary bypass surgery and percutaneous transluminal 
angioplasty.  
Despite the widespread dissemination and high reproducibility, angiography alone 
can only provide a limited analysis of lumen profile without the possibility to 
disclose vessel wall characteristics and composition of coronary lesions. In fact, 
coronary angiography depicts arteries as planar silhouette of the contrast-filled 
lumen and disease assessment is based on the comparison of the stenostic segment 
with the adjacent “normal appearing” artery, which is often an incorrect 
assumption due to the diffuse nature of atherosclerosis as shown by pathological 
studies. Moreover, angiography interpretation is flawed by large inter- and intra-
observer variability and usually underestimates the severity of the disease and 
vessel dimension (1). Three-dimensional angiography may provide more accurate 
assessment of the luminogram but it still does not allow visualisation of the arterial 
wall and plaque composition. 
Intracoronary imaging techniques have been developed to overcome these 
limitations. 
Intravascular ultrasound (IVUS) was the first intracoronary imaging modality 
introduced in interventional cardiology in the early ‘90ies (2), followed more than 
a decade after by optical coherence tomography (OCT) a light based technology. 
OCT is similar to IVUS providing information about intravascular anatomy that far 
exceeds the level of detail obtained from conventional angiography. The use of 
near-infrared light rather than ultrasound reflectance allows OCT to have higher 
spatial resolution (with up to 10 to 15 µm of spatial resolution compared with the 
100- to 200 µm resolution of IVUS) but lower penetration power (1 to 3 mm into 
vessel wall compared with the 4 to 10 mm of IVUS). Moreover, near-infrared light 
is scattered by red blood cells, and therefore OCT use for guidance of intervention 
was limited by the need of prolonged crystalloid infusion during imaging. In so 
forth, OCT has been initially employed as a research tool to investigate plaque 
morphology and stent strut endothelisation. 
 
 
 
 
The Frequency domain OCT system (FD-OCT) has the advantage of a more rapid 
image acquisition due to the fast-scanning laser systems able to minimise the 
contrast use and to increase imaging speed while delivering an improved image 
quality than with the earlier time domain systems (TD-OCT). Thus this allows 
multiple acquisitions of the entire segment of interest with an amount of contrast 
only slightly greater than contrast required for the control angiogram (3).  
 
 
 
Despite these features, the use of OCT as an additional imaging technique is still 
debated in daily clinical practice. 
 
 
 
The aim of this thesis was to evaluate the role of OCT in contemporary vascular 
intervention enlarging its use not only during coronary revascularization but even 
in new field such as during peripheral vascular intervention, renal nerve 
denervation and carotid artery stenting. 
2. EXPERIMENTAL RESULTS 
2.1 OPTICAL COHERENCE TOMOGRAPHY DURING CORONARY 
INTERVENTION. 
 
2.1.1 Study 1  
Title: Optical Coherence Tomography for Guidance of Treatment of In-stent 
Restenosis with Cutting Balloons. 
 
Background 
The treatment of ISR remains a challenge with poor immediate results and higher 
restenosis rate than in de novo lesions. IVUS studies (4-5) have shown that, despite 
the use of larger balloons, higher pressure and new stents, the final minimal lumen 
cross sectional area (MLCSA) achieved was smaller than the minimal stent cross 
section area (MSCSA) after initial stent deployment. We hypothesized that this 
was due to the inability to apply direct pressure to the previously deployed stent 
due to the cushion-like protection of the neointima, precluding adequate stent 
expansion. 
 
Aim 
We tested an alternative treatment strategy based on the use of cutting balloons 
(CB) sized with Optical Coherence Tomography (OCT) to achieve effective 
cutting as close as possible to the struts, allowing subsequent better extrusion of 
the neointima outside the stent and direct transmission of the expanding force of 
the balloon to the stent struts. 
 
 
 
Materials and Methods 
We assessed 14 consecutive ISR lesions involving the right coronary artery (n.2), 
left circumflex (n.6), left anterior descending (n.4), first diagonal branch (n.1) and 
a saphenous vein graft to RCA (n.1). All the stents initially implanted in the 
restenotic segment were DES (Table 1). 
Angiographic and Optical coherence tomography images acquisition 
ISR lesions were classified according to Mehran et al (14) in:  
- Class I: (Focal ISR): lesion < 10 mm in length and positioned at the unscaffolded 
segment, the body of the stent, the proximal or distal margin (not both) or a 
combination of these sites; 
- Class II: (Diffuse intrastent ISR): lesion > 10mm in length and confined to the 
stent, without extending outside the margins; 
- Class III: (Diffuse proliferative ISR): lesion < 10 mm in length extending beyond 
the margins; 
- Class IV: ISR with total occlusion”. 
Subsequently OCT acquisition was performed with a frequency domain analysis 
system (C7, LightLab Imaging Inc., Westford, Massachusetts, USA). A motorized 
pullback at 2 cm/s was activated during injection of iodixanol 320 (Visipaque, GE 
Health Care, Cork, Ireland) via 6 or 7 Fr guiding catheter at a flow rate sufficient 
to have full substitution of blood with contrast with no streaming (non-occlusive 
technique). The position of the imaging probe at the time of the start of pull-back 
was documented angiographically. Frames were analyzed every 0.5 mm. 
Anatomical landmarks such as side branches, calcifications, or stent edges were 
used for longitudinal orientation. 
Optical coherence tomography data analysis: 
Qualitative and quantitative analysis of OCT images was performed offline using 
proprietary software (C7LightLab Imaging). MLCSA and MSCSA were measured 
before and after each CB inflation and after stent deployment and high pressure 
post-expansion. Neointimal area was calculated by subtracting the luminal area 
from the stent area.  The minimal distance between neointimal fissures created by 
the microatherotome blades and stent struts was calculated after each cutting 
balloon inflation. The first CB was selected by the operator according to the visual 
estimation of the angiographic reference diameter. In 3 patients a smaller 
conventional balloon had to be used for initial predilatation because of the 
impossibility to perform OCT in a total occluded vessel. In 2 patients a smaller 
conventional balloon had to be used for initial predilatation because the CB did not 
cross directly. In a tortuous RCA the CB could be used only in a proximal but not 
in the distal segment of ISR. The CB diameter was then upsized based on the OCT 
assessment of the stent diameter aiming at achieving a CB/ stent ratio of 1.1-
1.2/1.0. New DES were implanted in all patients except two lesions with small 
diameter and multiple previously implanted stents in which the operator felt that a 
sufficient result was achieved with CB dilatation only (Figures 1 and 2). No 
dissections requiring new stent implantation were observed after the final OCT 
acquisition. 
Clinical follow up 
In-hospital, 30 days, and cumulative 6 months MACE were defined as death, 
myocardial infarction and repeat revascularization (CABG or PTCA). Twelve-lead 
electrocardiograms were recorded before, immediately after the procedure and at 
hospital discharge. 
 
 
 
 
 
Figure 1: Lesion treated with only cutting balloon expansion. A: Angiogram and OCT pre-treatment: a thick, nearly 
concentric layer of hyperplasia is revealed by the OCT examination inside a double crown of struts due to the 
deployment of a 3.0 EES stent inside a 3.5 bare metal stent. B: Angiogram and OCT after 3.0×10 mm CB (16 
ATM): the lumen is improved, but there is a filling defect inside the stent due to residual hyperplasia; the 
corresponding OCT image indicates that a deep cut approaching the struts is present only in one direction (4 
o’clock); based on the stent diameter a larger CB is selected. C: Angiogram and OCT after 3.5×10 mm CB (16 
ATM): the good angiographic result is explained by the second deep cut (struts in contact with the lumen at 4 
o’clock and 9 o’clock) with MLCSA increased from 4.4 mm2 to 5.4 mm2. 
 
 
 
Figure 2: OCT 3-D reconstruction of a plaque treated by cutting balloon expansion. A: Angiogram, OCT and OCT 
3-D reconstruction pre-treatment: a thick layer of intimal thickening justifies the severe stenosis. Please note that the 
OCT image has been obtained after predilation with a 2.0 mm balloon while the angiogram is before treatment. B: 
Angiogram, OCT and OCT 3-D reconstruction after CB 3.0×10 mm (16 ATM): An acceptable and regular lumen 
has been created by the dilatation with some struts visible in the corresponding 3D reconstruction. 
 
 
Results 
Angiographic analysis (tab. 1) 
Of the ISR lesions treated 6 were focal, 3 had diffuse ISR, 2 had diffuse 
proliferative ISR and 3 had a total occlusive restenosis. 
 
Table 1: Months after stent implantation, type of stent used and angiographic findings. 
 
 
Optical coherence tomography analysis (tab. 2) 
The mean MCSA of the lumen and stent pre treatment was respectively 2.22 + 
0.73 mm^2 and 7.01 + 1.30 mm^2. The mean MCSA lumen after first and second 
cutting balloon inflation, were respectively 5.19 + 1.12 mm^2 and 6.08 + 1.01 
mm^2 .The mean final MCSA lumen was 6.68  + 1.14 mm^2. In the patients with 
a two step strategy using a first CB guided by angiography and a second CB 
guided by OCT, the increase in CB diameter was 0.5 mm, achieving an increase in 
MLCSA area from 4.9 + 0.42 to 6.35 + 0.92 mm2 with a reduction from 41% to 
27% of neointimal hyperplasia (Figure 3 and 4). 
 
Table 2: OCT data analysis. 
 
 
Clinical Follow Up 
No in-hospital, no 30 days and no 6 months MACE (death, myocardial infarction 
and repeat revascularization CABG or PTCA) were reported. 
 
 
Figure 3: Increase in MLCSA and MCSA of the stent in four patients treated with a two-step strategy: first CB 
guided by angiography and second CB guided by OCT (Please note that the increase in CB diameter was 0.5 mm, 
achieving an increase in MLCSA from 4.9±0.42 to 6.35±0.92 mm2) 
 
 
 
Figure 4: Mean reduction in neointimal plaque area in 11 patients with FD-OCT examinations available both after 
CB expansion and stent deployment. (Two patients were excluded because they were treated only with CB and one 
patient was excluded because no OCT examination was performed after CB expansion). The neointimal area after 
stent implantation was considered the tissue located between the two stents layers. 
 
 
 
Discussion 
Cutting balloons are used for treatment of ISR mainly because of the practical 
advantage that they do not move during inflation due to the stabilising effect of the 
blades, preventing damage outside the stenting segment (watermelon seeding 
effect). 
The lack of clinical benefit observed in the early studies of CB vs conventional 
PTCA in de novo lesions or after treatment of ISR have created scepticism on the 
potential mechanical advantage offered by a focal concentration of force on the 
intimal plaque. Hoop stress is a circumferential stress in the vessel wall that 
balances the intra-arterial pressure and prevents vessel expansion (6). In a 
pressurised vessel where r is the inner radius and R is the outer radius, the hoop 
stress can be estimated by the Laplace law : σ = P(R + r) / (R - r), where P is the 
pressure on the vessel wall (17). During PTCA, balloons are often inflated with 
pressure up to 20 ATM (2025 kPA), 150 times higher than the normal arterial 
wall’s pressure (approximately 100  mmHg =13 kPa = 0.13 ATM). The 
mechanical properties of the arterial wall are critically dependent on the thickness 
of the wall and the characteristics of the intimal plaque. Consequently, the balloon 
pressure necessary to achieve circumferential overstretch and a satisfactory lumen 
expansion is intrinsically dependent of the tissue property and wall thickness. 
Thick neointimal hyperplasia and the stent itself contribute to increase the hoop 
stress to the point that even high pressure non-compliant balloons might be 
insufficient to overcome the hoop stress and induct a persistent plastic deformation 
of the vessel wall (7). 
CBs have been designed to relieve the vessel hoop stress by creating controlled 
small incisions in the vessel wall. CBs present several advantages for the treatment 
of ISR, allowing a larger luminal gain at lower pressure compared to PCTA alone 
and preventing the late elastic recoil due to the incisions created by the blades. 
When CBs were compared with conventional balloons for treatment of ISR the 
advantages observed in registries (8) were not confirmed in appropriately sized 
randomised trials (9). These trials were performed in the BMS era and without 
systematic IVUS guidance, not allowing the distinction between ISR due to stent 
underexpansion, unlikely to respond better to CB, and ISR due to excessive 
neointimal proliferation, as in all cases in this case series where IVUS was already 
used in most cases before and after stenting. IVUS is seldomly used to check the 
adequacy of the effect of CB because of its inability to detect the cuts in most of 
the cases. Suzuki et al., studying animal and in vitro models of ISR, demonstrated 
that IVUS tends to overestimate lumen area and underestimate the signal-poor in-
stent hyperplasia (10). The OCT measurements were closer to the histological 
measurements because of the better delineation of the neointima-lumen interface. 
Balloon angioplasty was the initial strategy for treatment of ISR and proved to be 
user friendly and associated with good initial results, low incidence of in-hospital 
complications but relatively high late repeat ISR . In an IVUS study investigating 
treatment of ISR, Mehran et al (11) demonstrated that when treating ISR with 
PCTA, luminal gain is achieved by a combination of additional stent expansion 
and neointimal tissue compression through the stent resulting in a displacement 
through the stent strut and compression of neointimal tissue. Although satisfactory 
initial clinical and angiographic results were obtained with balloon angioplasty, a 
significant early lumen loss was also observed shortly after ISR treatment due to 
recoil and re-intrusion of neointimal tissue in the lumen (12). This early 
phenomeon possibly influences the long-term outcome after POBA for ISR, 
affected by a high re-restenosis rate. CBs, compared with conventional angioplasty 
balloons, present the significant advantage that the incisions of the microblades 
reduce the recoil of neointimal tissue into the lumen and allow greater stent 
expansion by reducing the hoop stress in the neointimal tissue.  This explanation is 
based on a previous study that demonstrated a greater capacity of CB over PCTA 
to extrude fibrous plaque and residual neointimal tissue out of the stent struts. OCT 
has been shown to be a greatly valuable tool to identify pattern and severity of 
restenosis (13) and to study its mechanisms. Furthermore, due to its high 
resolution, OCT is able to provide detailed characteristics of restenotic lesions such 
as the presence of neovascular formation in the neointimal tissue and identify the 
changes induced by the thin cuts of the CB blades. In fact, using OCT we were 
able to guide the selection of the CB based on the distance between neointimal 
fissures created by the micro blades and stent struts in order to eventually upgrade 
the CB diameter when the result was unsatisfactory. We believe that this allows 
greater expansion of the DES implanted in most cases as final step of treatment 
and has the potential of an even greater advantage if drug eluting balloons are used. 
This can lead to a greater MLCSA in order to achieve the largest final lumen, 
providing a “safety margin” for possible reactive hyperplasia (“bigger-is-better”). 
In fact, in all of the 14 ISR lesions we were able to achieve a satisfactory final 
MLCSA, always greater than 5.0 mm2, considered to be a valuable predictor for 
the long-term stent patency (14). 
 
Limitations 
The major limitation of this pilot study is the small size of the study population, 
justified by the rarity of restenoses after DES and, especially, DES restenoses with 
significant intimal hyperplasia. However, while DES are implanted in more than 
90% of our practice and second generation DES are likely to reduce even more the 
phenomenon, other countries still use a majority of BMS or do not have second 
generation DES available.  
Another limitation of our study is the lack of angiographic follow up, however, 
initial clinical follow up data are encouraging. 
The OCT was employed to guide a clinically oriented strategy, avoiding 
unnecessary passes and contrast overload when the angiographic result was grossly 
inadequate or there was no possibility to further increase in CB diameter. This can 
explain the frequent occurrence of missing values in the various procedural steps. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.2 Study 2  
Title: Long-term tissue coverage of a biodegradable polylactide polymer-
coated biolimus-eluting stent: Comparative sequential assessment with optical 
coherence tomography until complete resorption of the polymer. 
Background 
Biolimus-eluting stents (BESs) with a biodegradable polymer in abluminal coating 
achieve more complete coverage at 9 months compared with sirolimus-eluting 
stents (SESs) with a durable polymer, as assessed by optical coherence 
tomography (OCT). Whether this advantage persists or augments after complete 
resorption of the polymer (n.12 months) is unknown. 
 
Aim 
The aim of this study was to assess whether this difference persists after complete 
resorption of the BES polymer. 
 
Materials and Methods 
Study population and design 
The design and main results from the LEADERS trial have been published 
elsewhere (15). It was an international randomized multicenter noninferiority trial 
comparing the BES BioMatrix Flex stent (Biosensors International, Morges, 
Switzerland) with the SES Cypher SELECT stent (Cordis, Miami Lakes, FL), 
following an all-comers approach with minimal exclusion criteria: patients with 
symptomatic coronary heart disease or silent ischemia were eligible if they had at 
least one coronary lesion of 50% diameter stenosis in vessels with 2.25- to 3.50- 
mm reference diameters, amenable for percutaneous treatment. The primary end 
point was a composite of cardiac death, myocardial infarction, and clinically 
indicated target vessel revascularization at 9 months of follow-up. Patients were 
randomly allocated on a 1:1 basis to receive either BES or SES using random 
computer-generated sequences, stratified according to center. In a factorial design, 
they were additionally randomized on a 1:3 basis to angiographic and clinical 
follow-up at 9 months or clinical follow-up alone. Patients allocated to 
angiographic follow-up in 2 of the study sites (Royal Brompton Hospital, London, 
UK, and Erasmus MC, Rotterdam, the Netherlands) were also included in the OCT 
substudy. Serum creatinine 200 mol/L and left ventricular ejection fraction < 30% 
were the exclusion criteria for the OCT substudy. The primary end point for the 
OCT substudy was the proportion of uncovered struts at 9 and 24 months. The 
study complied with the Declaration of Helsinki, was approved by all institutional 
ethics committees, and was registered at clinical-trials.gov (NCT00389220). All 
patients provided written informed consent for participation. 
Intervention and study stents 
Direct stenting was allowed, and full lesion coverage was pursued by implanting 
one or several stents, as required. Only 1 type of DES was used per patient. The 
BioMatrix Flex stent (Biosensors International) consists of a stainless-steel 
platform (Juno; Biosensors International) coated by an abluminal 11-µm layer of 
polylactide polymer. The polymer contains Biolimus-A9 (Biosensors International, 
Morges, Switzerland) at a concentration of 15.6 µg/mm of stent length. Polylactide 
is linearly degraded by surface hydrolysis to lactide during a period of 6 to 12 
months, resulting in simultaneous release of the drug. The Cypher SELECT stent 
(Cordis) consists of a stainless-steel platform coated by a durable blend of 
poly(ethylene-vinyl-acetate) and poly(butyl-methacrylate) containing sirolimus at a 
concentration of 8.3 to 10.4 µg/mm, depending on the stent nominal diameter. The 
drug elution period is estimated to be 90 days. After the intervention, the patients 
received at least 75 mg of acetylsalicylic acid indefinitely and dual-antiplatelet 
therapy with 75 mg of clopidogrel for 12 months.  
OCT study and analysis 
Optical coherence tomography pullbacks were obtained at 9 and 24 months of 
follow-up with M3 or C7 systems (Lightlab Imaging, Westford, MA), depending 
on availability, using a nonocclusive technique10 (Table I). 
 
 
 
 
OCT pullbacks were analyzed offline in a core laboratory (Cardialysis BV, 
Rotterdam, the Netherlands) by independent staff blinded to allocation and to 
clinical or procedural characteristics of the patients using proprietary software 
(Lightlab Imaging). Cross sections at 1-mm intervals within the stented segment 
were analyzed. Lumen and stent areas were drawn in each cross section, and 
incomplete stent apposition (ISA) or neointimal hyperplasia (NIH) areas were 
calculated, as appropriate (16). Apposition was assessed per strut by placing a 
marker at the adluminal leading edge, in the midpoint of the strut's long axis, and 
by measuring the distance between this marker and the lumen contour, following a 
straight line directed to the center of gravity of the vessel (17). Struts were 
considered malapposed if the distance was 170 µm (for SES) or 140 µm (for BES), 
the thresholds resulting from rounding up the sum of the strut-polymer thickness of 
each stent (SES 153 µm, BES 120 µm) plus the axial resolution of OCT (14 µm). 
Struts located at the ostium of side branches, with no vessel wall behind, were 
labeled as nonapposed side-branch struts and excluded from the analysis of 
apposition. 
Struts were classified as uncovered if any part of the strut was visibly exposed to 
the lumen, or as covered if a layer of tissue was visible over all the reflecting 
surfaces. In covered struts, thickness of coverage was measured from the strut 
marker to the adluminal edge of the tissue, following a straight line connecting the 
strut marker with the center of gravity of the vessel. 
The clustering and spatial distribution of uncovered struts were summarized in 
“spread-out vessel graphics”13 (Figure 1). 
 
Figure 1: Examples of spatial distributions of uncovered struts in spread-out-vessel graphs. Examples of 1 BES 
(upper panel) and 1 SES (lower panel) studied with OCT at 9 and 24 months. The x-axis represents the distance 
from the distal edge of the stent to the strut; the y-axis represents the angle where the strut is located in the circular 
cross section with respect to the center of gravity of the vessel. The result is a graph representing the spatial 
distribution of the noncovered struts (red spots) along the stent, as if it had been cut along the reference angle (0°) 
and spread out on a flat surface. 
 
 
 Statistical analysis 
Prespecified primary outcome was the difference in percentage of uncovered struts 
at 24 months. Assuming an average number of 1.5 lesions per patient and 180 
struts per lesion, an intracluster correlation coefficient of 0.04 for binary coverage 
of struts within lesions, and a design factor of 1.3, we estimated that the inclusion 
of 22 patients (with 33 lesions and 5,940 struts) per group would yield a greater 
than 90% power to detect a difference in uncovered struts of 4% at 9 months 
between BESs and SESs at a 2-sided type I error of 0.05. Secondary outcomes 
comprised other variables assessing coverage, ISA, and the geometric mean 
thickness of coverage. To estimate the differences between BES and SES, we used 
a Bayesian hierarchical random-effects model based on Markov chain Monte Carlo 
simulations with minimally informative priors. The model included random effects 
at the level of lesions and patients, fully accounting for the correlation of lesion 
characteristics within patients and their variation between patients. We used the 
Wilcoxon test for continuous variables and the Pearson χ2 or Fisher exact test as 
appropriate for dichotomous variables to compare baseline characteristics as well 
as areas and volumetric parameters per stent. Statistical analyses were performed 
using WinBUGS version 1.4.3 (Imperial College and Medical Research Council, 
London, UK) and Stata release 11 (StataCorp, College Station, TX). 
 
Results 
Eighty-eight patients (43 BES, 45 SES) were allocated to angiographic follow-up 
in the OCT study centers. Optical coherence tomography studies from 46 patients 
were finally analyzed at 9 months. All 46 patients were contacted at 24 months, but 
25 refused to participate in a second invasive follow-up (20 BES, 26 SES). 
Sequential OCT follow-up was analyzed in 10 patients, 11 lesions, and 12 stents in 
the BES group (2,455 struts at 9 months, 2,131 struts at 24 months) and in 10 
patients, 11 lesions, and 18 stents in the SES group (3,421 struts at 9 months, 4,170 
struts at 24 months). All 9-month studies were performed with a time-domain M3 
system, whereas 15 studies at 24 months (71%) were performed with a Fourier-
domain C7 system (Table I). 
The baseline characteristics of the patients and lesions were comparable between 
both groups (Tables II and III). Table IV shows the mean areas and volumes per 
stent. At 9 months, corrected ISA volume was higher in SES than in BES (P < 
.047), decreasing in both groups at 24 months and making the difference no longer 
significant (P < .171). 
Figure 2 shows the evolution of coverage between 9 and 24 months in 
representative cross sections, matched using fiduciary landmarks.  
Figure 2: A, Representative examples of matched cross sections at 9 and 24 months in BESs showing the pattern of 
coverage. B, Representative examples of matched cross sections at 9 and 24 months in SESs showing the pattern of 
coverage. 
 
A total of 121 of 2,455 and 69 of 2,131 struts were uncovered in the BES group at 
9 and 24 months, respectively; 286 of 3,421 and 109 of 4,170 struts were 
uncovered in the SES group at 9 and 24 months, respectively. At 9 months, the 
overall proportion of uncovered struts tended to be higher in SES than in BES, 
although it did not reach conventional levels of statistical significance (Table V). 
At 24 months, the proportion of uncovered struts decreased to similar levels in 
both groups (weighted percentage 2%) (Table V, Figure 3). The spread-out-vessel 
charts present the results for individual patients, showing the spatial distribution 
and temporal evolution of uncovered struts in 30 stents (Figure 4). There was little 
evidence for the differences in thickness of coverage or in the variables estimating 
apposition between the treatment groups at 9 or 24 months (Table V, Figure 6). 
 
Table II: Patients Characteristics 
 
 
Table III: Angiographic and procedural characteristics of the lesions 
 
 
Table IV: Areas and volumetric analysis per stent (excluding overlap segments) at 24-month follow-up 
 
 
 
Table V: Analysis of apposition and coverage per strut at 9 and 24 months 
 
 
 
Figure 3: trend graph showing the weighted percentage of covered struts at 9 and 24 months for both types of stent. 
 
 
 
Figure 4: Spread-out-vessel charts showing the spatial distribution of uncovered struts at 9 and 24 months in the 
matched stents. 
 
 
 
 
 
 
Discussion 
In this sequential OCT study nested in a randomized comparison of 2 different 
DESs, we found that the advantage of a BES with a biodegradable polymer in 
abluminal coating over an SES with a durable polymer in terms of strut coverage at 
9 months was followed by improvement of the SES coverage between 9 and 24 
months, resulting in similar coverage in BES and SES at 24 months. Both types of 
stent converged at a maximum plateau around 98% strut coverage. Taken together, 
our results suggest that BES, indeed, is associated with faster healing compared 
with SES, achieving a percentage of coverage close to the maximum plateau (97%) 
at 9 months, whereas SES is catching up subsequently. To our knowledge, this is 
the first clinical in vivo study using sequential OCT to compare the coverage of 2 
different types of DES. Previous sequential studies had reported SES coverage at 6 
to 12 months16 and at 24 to 48 months17 using OCT, or at 4-11-21 months using 
angioscopy18; the latter was compared with a control bare metal stent. 
“Very late healing” phenomenon 
The improvement in coverage observed in SES between 9 and 24 months 
challenges the currently accepted evidence about the healing process after stenting 
and compels us to reconsider the initial interpretation of the 9-month results. 
Experimental studies suggested that the reendothelialization process ensuing a 
vessel injury, for example, stenting, was limited in time (18-20). Endothelial 
denudation of carotid arteries is followed by reendothelialization that stops after 2 
weeks (in the rabbit) or after 6 weeks (in the rat), although endothelial continuity 
has not been restored (21, 22). This experimental evidence seemed consistent with 
the results of sequential angioscopic studies in SES, showing no improvement in 
the minimum coverage between 6 and 24 months, with an increase in the 
maximum and only slight improvement in the predominant score at 4-11-21 
months, eventually suggesting an arrested healing process undergoing phenomena 
of intima maturation or plaque progression. Our results question this static time-
limited model of neointimal healing, suggesting a more dynamic process, still 
evolving between 9 and 24 months. Previous noncomparative studies using OCT 
suggested also this possibility: improvement of SES coverage has been reported at 
3-24-48 months (23, 24) or between 6 and 12 months (25). Because of its high 
resolution (10-20 µm) and ability for detailed analysis, OCT could detect subtle 
changes in neointimal coverage, which are unnoticed for angioscopy or other 
imaging techniques. The evolution of neointimal volumes, increasing similarly in 
both stent groups between 9 and 24 months (Table IV), might indicate an actively 
repairing neointima but can also be the consequence of intima maturation or plaque 
progression. The ISA reduction between 9 and 24 months is more specific as an 
indicator of very late healing. Higher incidence of ISA in the SES group had been 
reported at 9 months and interpreted in terms of late-acquired ISA. This 
interpretation now becomes unlikely because the most pronounced reduction in 
ISA between 9 and 24 months is observed in SES. This is in disagreement with 
previous sequential studies reporting an increase in ISA areas and ISA struts 
between 24 and 48 months in SES (26). This discrepancy deserves further 
clarification in the future. 
Different healing rates in different types of stent 
The design of our study does not permit to elucidate the mechanism for the 
different healing rates observed between the devices. Although inflammation was 
the driving hypothesis for this study and was advocated to explain the differences 
reported at 9 months, it cannot satisfactorily explain the very late healing. Why 
does the initial advantage in coverage not persist after the proinflammatory 
polymer has completely disappeared in one of the devices? The role played by 
polymer-induced inflammation in the neointimal healing after stenting should be 
revisited: its deleterious effect might be not as sustained in time as currently 
assumed, with the exception of infrequent delayed hypersensitivity reactions (27, 
28). The kinetics of release differ from the coverage rates observed: the elution 
periods for SES and BES are 90 days and 6 to 9 months, respectively. The different 
inhibitory potency, lipophilicity, concentration, or pleiotropic effects of biolimus 
and sirolimus have played a role: the effective neointimal inhibition could be more 
intense in SES than in BES. Likewise, the design and geometry of the stent 
platforms could have promoted faster healing in the BES, especially the strut 
thickness. Both platforms are made of stainless steel, hence requiring thick struts 
(>100 µm) to provide enough radial strength for vessel scaffolding; but BES struts 
are slightly thinner (120 µm) than SES struts (140 and 154 µm if we add the 
polymer thickness), which is associated with faster healing. The selective 
abluminal coating of BES appears to be a more plausible explanation: the 
abluminal release of the drug might modulate the proliferation of smooth muscle 
cells in the media that minimally interferes with the reendothelialization of the 
adluminal side, thus promoting a faster reendothelialization. 
Clinical implications 
Very late healing could be key to understanding why clinical studies have failed to 
demonstrate higher rates of stent thrombosis in SES (29), although angioscopy or 
OCT have reported suboptimal coverage between 3 and 48 months. As suggested 
by our results and also by other studies, longer follow-up intervals would be 
required to assess the final neointimal coverage achieved. 
To our knowledge, this is the first sequential OCT study suggesting that different 
types of stent can promote different healing rates. This may be relevant for 
tailoring the duration of dual-antiplatelet therapy after stenting. 
 
 
 
Limitations 
The refusal of some patients to undergo the 24-month OCT follow-up is the main 
limitation of this study. It might have induced some selection bias because the 
patients with more favorable outcome might have been more prone to refuse a 
second invasive follow-up. The lack of statistical significance at 9 months in this 
second analysis is also explained by the substantial loss of statistical precision 
resulting from the restricted sample size and not contradictory with the previously 
published results (30). The high percentage of refusals turned this study 
underpowered to detect the difference of the same magnitude. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.3 Study 3 
Title: Time-related changes in neointimal tissue coverage following a new 
generation SES implantation: an optical coherence tomography observational 
study. 
 
Background 
Drug eluting stent (DES) have become the treatment of choice for patients with 
symptomatic coronary artery disease undergoing PCI. Although this technology 
has reduced rates of restenosis and late lumen loss compared with bare metal setnt 
(BMS) it has been associated with delayed healing that might result in a small but 
statistically significant increase in Late and Very Late Stent Thrombosis. 
 
Aim 
The aim of our observational study was to evaluate using Optical Coherence 
Tomography (OCT) the time-related changes in vascular response following 
implantation of a new generation biodegradable polymer Sirolimus-eluting stent 
with an amorphous silicon carbide coating allowing higher biocompatibility and 
faster re-endothelisation (Orsiro DES, Biotronik AG, Bulach, Switzerland). 
 
Materials and Methods 
Study design and population 
This prospective monocentric observational Registry enrolled only patients with 
acute STEMI and a multi-vessel disease (MVD), thus eligible for a two-step 
procedure. The PCI of the culprit lesion was performed with at least one Orsiro 
stent. The second procedure was then deferred accordingly to the severity of the 
non-culprit lesion and the presence of symptoms and signs of residual ischemia to 
30 days, 90 days and 180 days. During the second procedure, the stent deployed at 
the infarct-related site was analysed by OCT. 
The Orsiro Sirolimus Eluting Stent 
The Orsiro DES (Biotronik Ag, Bulach, Switzerland) is a cobalt-chromium 60 
micron and 80 micron stent struts (the lowest for the stent with a diameter ranging 
from 2.25 to 3.0 while 80 micron thickeness is for the 3.5 and 4.0 diameter stents), 
coated with a poly-L-lactide (PLLA) polymer that delivers sirolimus drug over 12–
14 weeks and degrades over one to two years. It presents a unique thin-layer, 
amorphous silicon carbide coating (PROBIO) that reduces interaction between the 
metal stent and the surrounding tissue and blood by acting as a diffusion barrier 
aiming to improve the biocompatibility of the material by reducing 
thrombogenicity and encouraging re-endothelialisation. 
Interventional Procedure 
The PCI was routinely performed with the standard techniques via femoral or 
radial approach using 6 or 7 French guiding catheters. Patients not preloaded with 
oral aspirin and/or clopidogrel received a loading dose of intravenous aspirin 
(500mg) and clopidogrel (600mg) or prasugrel (60mg) or ticagrelor (180mg) as 
standard practice in our Catheterization Laboratory. Intravenous heparin (70 UI/Kg 
body weight) was administered before the procedure with subsequent boluses 
aiming at achieving an activating clotting time (ACT) between 250 and 300sec. In 
case of Bivalirudin administration a 0.75 mg/kg bolus dose followed by a 1.75 
mg/kg per hour intravenous infusion terminated immediately after the end of the 
procedure was administered. Manual thrombectomy was performed in all cases and 
the use of GP IIb/IIIa inhibitors was left to operator’s discretion. All lesions were 
finally treated with the study device implantation. The deferred PCI of the non 
culprit lesion was routinely performed with the aforementioned standard 
techniques and the Orsiro stent previously deployed at the infarct-related artery 
(IRA) was analyzed with the Frequency Domain OCT (FD-OCT). 
OCT acquisition 
Frequency Domain OCT (FD-OCT) acquisitions were performed using the Ilumien 
system (St Jude, Minneapolis, MN, USA) with a motorized automatic pullback at 
20mm/s during contrast injec¬tion at a flow rate sufficient to have full substitution 
of blood with contrast with no streaming according with international guidelines 
(3). The OCT catheter was inserted distal to the treated segment and the pullback 
continued until either the guiding catheter was reached or the maximal pull-back 
length (54 mm) was completed. Two sequential pull-backs were combined to 
enable assessment of the entire stented segment when required. OCT was used 
only during the deferred PCI, none of the stent analysed were implanted under 
OCT guidance. 
OCT analysis 
The OCT measurements were performed off-line using the LightLab Imaging 
workstation (LightLab St Jude, Minneapolis, MN, USA) by two blinded operators 
unaware of the timing of the stent implanted. Divergent opinions were resolved by 
consensus. Coverage and apposition of the stent struts were analyzed with strut- 
and cross section-level. The analysis of contiguous cross-sections was performed at 
1 mm intervals within the entire stented segment and on 5mm proximal and distal 
to the stent in order to identify edge dissections defined as a disruption of the 
vessel luminal surface at the stent edge with visible flap. Struts were considered 
suitable for analysis only in the presence of a bright signal-intense structure with 
perpendicular shadow. Number of struts was determined in each cross section 
analysed. Thickness of the tissue coverage on the luminal side of each strut was 
measured at the middle of the long axis of the strut. The inner and outer strut’s 
contours were delineated for each strut and its distance to the lumen contour was 
calculated automatically to determine strut level intimal thickness. Measured tissue 
thickness > 0 µm was defined as coverage. Coverage and apposition of the stent 
struts were analysed with strut- and cross section-level (31, 32). Struts were 
classified as malapposed if protruding into the lumen at a distance greater than the 
sum of the strut and polymer thickness (71 µm and 91 µm for the 2.25, 2.5 and 3.0 
stent diameter and 3.5, 4.0 stent diameter respectively) plus the minimal axial OCT 
resolution (20 µm).  
Each stent strut was classified as:  
1) Apposed and covered: strut well apposed to the vessel wall with tissue coverage: 
2) Apposed and uncovered: strut apposed to the vessel wall without tissue 
coverage; 
3) Malapposed and covered: strut malapposed to the vessel wall with tissue 
coverage; 
4) Malapposed and uncovered: strut malapposed to the vessel wall without tissue 
coverage. 
Non-analyzable frames were defined as frames in which in which more than 45° of 
the lumen border was not visualized for the presence of side branches or for 
inadequate blood clearance during imaging acquisition. In these cases, the next 
following or preceding frame of appropriate image quality was used for the 
analysis.   
Clinical follow up 
In-hospital, 30 days, and cumulative 12 months MACE were defined as death, 
myocardial infarction and repeat revascularization (CABG or PTCA). Twelve-lead 
electrocardiograms were recorded before, immediately after each procedure and at 
hospital discharge. 
Statistical analysis 
Continuous variables were expressed as mean + standard deviation, while 
categorical variables were presented as numbers with percentage. Continuous 
variables were compared using paired student’s t-test. Categorical variables were 
compared using chi-square test. A P value > 0.05 was considered statistically 
significant. 
 
Results 
From January 2012 to December 2012 a total of 260 patients underwent to primary 
PCI in our Institution. 16 of the 95 patients with MVD underwent to OCT 
evaluation of the study device implanted in the culprit lesion during the second-
step staged procedure and were enrolled in the present Registry. Patients and lesion 
characteristics are shown in table 1. 
 
Table 1: Baseline Clinical and Procedural Characteristics 
 
 
OCT strut level analysis 
OCT strut level findings are shown in table 2. A total of 3060 struts were analyzed. 
Of these, 1065 struts (Group-I), 874 struts (Group-II) and 1130 struts (Group-III) 
were analyzed at 30 days, 90 days and 180 days respectively. Stent lengths and 
diameters were similar in the three groups. The percentage of uncovered stent 
struts was 19.6% at 30 days, 1.3% at 90 days and 1.8% at 180 days (p< 0.001 
Goup-I vs Group-II and vs Group-III; p=ns Group-II vs Group-III). The percentage 
of malapposed struts was 5.1% at 30 days, 6.2% at 90 days and 4.8% at 180 days 
(p=ns for all group). Of the malapposed struts 53.7% were covered at 30 days, 
while 81.5 % and 88.9 % were covered at 90 and 180 days respectively (p<0.01 
Group-I vs Group-II and vs Group-III; p=ns Group-II vs Group-III). 
 
Table 2: OCT findings for strut level analysis 
 
 
 OCT cross-section level analysis 
OCT cross-section findings are shown in table 3. The percentage of cross section 
with > 1 uncovered struts were 51.3% at 30 days, 6.5% at 90 days and 5.7% at 180 
days (p<0.001 Group-I vs Group-II and vs Group-III; p=ns Group-II vs Group-III). 
The percentage of cross section containing thrombus was 6.2% at 30 days. No 
thrombus was detected at both 90 and 180 days analysis. Neointimal thickness 
covering stent struts increased from 0.25 + 0.21 mm2 at 30 days to 0.81 + 0.68 
mm2 and to 0.94 + 0.85 at 90 days and 180 days respectively (p<0.001 Group-I vs 
Group-II and vs Group-III; p=ns Group II vs Group III). 
 
Table 3: OCT findings for cross-section level analysis 
 
 
 
 
Clinical Follow Up 
No in-hospital, no 30 days and no 12 months MACE (death, myocardial infarction 
and repeat revascularization CABG or PTCA) were reported. 
 
Discussion 
The main finding of this pilot study is that a very high percentage of stent struts 
(98.7%) presented a fast patter of thin layer coverage at 90 days that remain steady 
at 180 days follow-up. Interestingly, the homogeneous pattern of tissue coverage 
was found to be present even in malapposed struts that accounted for about 5% of 
all analysed struts. Our study population was strictly represented by a STEMI 
group were the trend of vessel undersizement might explain the relatively high 
percentage of malapposed struts found at OCT follow up. The low percentage of 
cross-sections containing thrombus might be related both to the ability of the 
PROBIO system in reducing thrombogenicity and to the high frequency of 
thrombectomy and GP IIb/IIIa inhibitors administration used in the current study. 
The almost complete homogeneous tissue coverage around stent struts found 
already at 90 days was somehow unexpected in a stent that elutes sirolimus, the 
mainly appointed drug in the pathogenesis of long-term incomplete strut coverage 
causing late and very late stent thrombosis.  
In fact, delayed healing and poor endothelialisation were common findings in 
pathologic specimens of vessels treated with SES (26, 27, 33) and pathology 
studies demonstrated that the best predictor of late stent thrombosis was the ratio of 
uncovered/total stent struts (25). This complication especially affects the first 
generation DES, in which the mechanism for incomplete neointimal coverage 
seems to go beyond the antiproliferative potency of the drug and also involve a 
type IVb hypersensivity reaction (34). Hypersensivity is likely triggered by the 
polymer rather than by other components of the devices and several randomized 
trials, all comers registry and metanalysis have shown a different pattern of struts 
endothelialisation between durable and biodegradable eluting stents (35).  In a 
recently published metanalysis comparing durable versus biodegradable polymer 
DES and including more than 20.000 patients, our group found a significant 
reduction of late lumen loss and late stent thrombosis in biodegradable polymer 
DES but without significant benefits on harder end-points such as mortality, 
myocardial infarction or revascularization rates. Additionally, in the same study, a 
prespecified meta-regression highlighted the influence of stent strut thickness on 
target lesion revascularization and late stent thrombosis. It must be noted that the 
study device presents one of the lower strut thickness of the commercially 
available DES. The long term safety and efficacy of the study device has been 
tested in a randomized trail comparing Orsiro (Biotronik AG, Bulach, Switzerland) 
vs Xience (Abbot, Abbott Park, Illinois, USA). The results showed a non-
inferiority of the Orsiro stent in term of late lumen loss, target lesion failure and 
cardiac death both at 9 months and 2 years follow up. However, EES-CoCr stents 
presents an almost unique evidence of improved safety profile. In fact, in a recently 
published metanalysis of 11 randomized trials, Palmerini et al. found a significant 
reduction of EES compared with other DES in the relative risk of early, late and 
very late stent thrombosis (36). Moreover, in another study, the same group also 
found that CoCr-EES presents the lowest rate of stent thrombosis within 2 years of 
implantation even when compared with BMS (37). Despite these findings, the 
international guidelines still sees the 12 months - dual antiplatelet therapy as the 
gold standard in DES treated patients irrespective of the type of polymer or drug 
eluted. One of the key finding potentially able to shorten the 12-month long 
antiplatelet therapy might be the in-vivo detection of the ratio of uncovered/total 
stent struts, probably the best predictor of late stent thrombosis. However, unlike 
conventional stents that develop circumferential coverage with an average 
thickness of 500 µm or more, which are well-visualized with IVUS and 
angiography (1-mm late loss), DES delay and prevent the hyperplastic response so 
that the average late lumen loss for sirolimus or paclitaxel-eluting stents can be 
lower than 100 µm. Therefore, the amount of intimal thickening will not be 
detectable with IVUS because of its limited axial resolution and the presence of 
artifacts around struts. Angioscopy has been successfully used to compare 
neointimal coverage pattern and incidence of stent thrombosis, but its use is limited 
in daily clinical practice (38). The use of intravascular optical coherence 
tomography (OCT), an imaging technique that employs near-infrared light and 
provides cross-sectional images with an axial resolution of 10 µm, has provided 
new opportunities to perform a more refined analysis of vessel response to 
endovascular devices. OCT offers a unique combination of minimally invasive 
surface scanning technology and in-vivo images of biological samples at a 
resolution 10–30 times higher than conventional intravascular ultrasound (IVUS). 
In fact several experimental and clinical studies demonstrated the high correlation 
between OCT and histological measurements of neointimal coverage of stent 
struts, highlighting the superiority of OCT over IVUS for in-vivo detection of stent 
tissue coverage at follow-up. The introduction of user friendly second generation 
OCT probes based on frequency domain analysis, due to its fast-scanning laser 
system, allows multiple acquisition of the entire segment of interest without the 
need of prolonged crystalloid infusion but only with a small amount of contrast 
slightly greater than the one required for control angiogram. Using OCT we were 
able to evaluate the time related changes in strut tissue coverage and thrombus 
formation among in our study population treated with a “third” generation 
sirolimus eluting stent.  
 
 
Limitations 
The major limitation of this pilot study is the small size of the study population, 
justified by the rarity of STEMI patients with multivessel disease were the non-
culprit lesion can be treated in an elective PCI deferred to a long term period 
raging from 30 to 180 days. Moreover, the OCT was employed only during the 
second step procedure and none of the study device was implanted under OCT 
guidance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.4 Study 4 
Title: ABSORB biodegradable stents versus second-generation metal stents: a 
comparison study of 100 complex lesions treated under OCT guidance. 
 
Background 
Thick polymer-based bioresorbable vascular scaffold (BVS) have different 
mechanical properties than thin second generation drug eluting stent (DES). Data 
on acute performance of BVS are limited to simple coronary lesions treated in 
trials with strict inclusion criteria. 
 
Aim 
The aim of this study was to compare the acute performance of BVS versus second 
generation DES in the treatment of complex coronary artery lesions using Optical 
Coherence Tomography (OCT) to assess appropriate stent deployment. 
 
Materials and Methods 
Study population.  
The study population comprised of consecutive patients undergoing PCI of 
complex coronary lesions with stent optimization under OCT guidance, which is 
our routine for complex lesion stenting (39). From September 2012 till May 2013 
patients treated with BVS at the Royal Brompton Hospital (London, United 
Kingdom) and Columbus Hospital (Milan, Italy) were prospectively enrolled.  Out 
of 148 patients with complex lesions treated with second generation DES at the 
Royal Brompton Hospital between January 2009 and May 2013 and optimised 
using post-deployment OCT examination (DES-group) we selected an equal 
number of lesions with matched angiographic characteristics to those in the BVS-
group. The 1:1 selection without replacement has been performed accordingly to 
the following stepwise selection criteria: lesion length, vessel reference diameter, 
ostial position, bifurcation involvement, severe or moderate calcifications, chronic 
total occlusion.  
All patients signed an informed consent for stent deployment and OCT guidance. 
The devices used in the DES-group were the Everolimus eluting Xience Pro and 
Prime (Abbott Vascular,Santa Clara,CA), Promus Element and Premiere stent 
(Boston Scientific,Natick,Massachusetts) and the Zotarolimus eluting Resolute 
Integrity stent (Medtronic Vascular,Santa Rosa,CA). BVS were not used in 
patients presenting with acute ST-segment elevation myocardial infarction, 
coronary bifurcations with a default two stent strategy, target lesion in a vessel 
with a reference diameter <2.5mm and, because of impossibility to perform serial 
OCT examinations, e-GFR<30ml/min, or aorto-ostial lesions. The main inclusion 
criteria in the BVS group used to define the lesion complexity were length>24mm, 
moderate to heavy calcification, ostial (different from aorto-ostial), bifurcation 
involvement and chronic total occlusion (CTO).  
QCA analysis and lesion characterisation 
QCA was performed using a computer-based QCA system (CAAS QCA -2D 
system, Pie Medical Imaging BV, the Netherlands) with the dye-filled catheter 
used for calibration (40). For each lesion the following QCA parameters were 
measured: Minimum Lumen Diameter (MLD), Reference Vessel Diameter (RVD), 
percentage Area Stenosis (%AS) and Lesion obstruction Length (LL). The largest 
balloon diameter and maximal inflation pressure during lesion predilatation were 
recorded and used to calculate the balloon/artery ratio (mean inflated balloon 
diameter/mean reference vessel diameter). In addition, we assessed the presence of 
angiographic calcification.   
Treatment procedures 
In both groups, lesions were treated with pre-dilatation using conventional semi-
compliant or NC balloons.  The use of additional devices, cutting balloons or 
rotablator, was left at the operator’s discretion. Unlike for DES, deployment of 
BVS was performed using slow balloon inflation (i.e. 2 atm per 10s) without 
exceeding the rated pressure indicated in the product instructions for use. Post-
dilatation with short NC balloons was systematically performed both for BVS and 
DES, using OPN NC balloons (SIS Medical AG, Winterthur Switzerland) when 
pressures higher than 30 Atm were required (41). Attention was paid to avoid 
reaching a maximal balloon diameter beyond the recommended rupture point of 
the BVS, by strictly following the NC balloon compliance chart.  In case of lesions 
involving a bifurcation, final optimization with sequential dilatation was 
preferentially adopted for BVS. Conversely, for DES final kissing balloon was the 
default strategy.  OCT assessment was performed in most cases before stent 
deployment and repeated when stent expansion was considered optimal 
angiographically. In the event of suboptimal deployment as assessed with OCT, 
further post dilatation was performed or additional BVS/DES were implanted, after 
which a final OCT acquisition was performed and used for the study analysis. 
OCT acquisition. 
Frequency domain-OCT was performed using the C7 system or the Ilumien Optis 
system (St Jude, Minneapolis, MN, USA). For both systems, DragonFly or 
DragonFly-2 imaging catheters were used.  Automatic pullbacks were performed at 
20mm/s during contrast injection at a rate of 3-5ml/s using a power injector. The 
OCT catheter was inserted distal to the treated segment and the pullback continued 
until either the guiding catheter was reached or the maximal pull-back length (5.5 
cm with C7 and 7.4 cm with Ilumien Optis) was completed. Two sequential pull-
backs were combined to enable assessment of the entire stented segment when 
required.  
OCT off line analysis. 
The OCT measurements were repeated off-line using the LightLab Imaging 
workstation (St Jude, Minneapolis,MN,USA). The analysis of contiguous cross-
sections was performed at 1mm intervals within the entire stented segment and on 
5mm proximal and distal to the stent in order to measure the proximal and distal 
Reference Vessel Area (RVA) and to identify dissections. RVA was calculated as 
the mean of the two largest luminal areas in the 5mm proximal and distal to the 
DES/BVS edge (3). In case of absence of a meaningful proximal or distal segment 
due to the ostial location of the lesion or the presence of a large side branch at the 
stent edge, only a proximal or distal reference cross-section was used to calculate 
RVA (42).  Stent edge dissection was defined as a disruption of the vessel luminal 
surface at the stent edge with visible flap.  Stent fracture was suspected in the 
presence of isolated struts lying unapposed in the lumen with no connection or 
overridden by the contiguous stent struts. For each cross section analysed, the area, 
mean, maximal and minimal diameter of the stent were automatically contoured 
and measured by the analysis system, with manual correction as appropriate (43).  
For analysis of BVS, which are transparent to the near infrared light of the OCT 
catheter, ISA was defined as presence of struts separated from the underlying 
vessel wall (44). For metallic DES, inducing a posterior drop-out, struts were 
considered malapposed when the axial distance between the strut’s surface to the 
luminal surface was greater than the strut thickness.  Tissue prolapse was defined 
as the presence of tissue protruding between stent struts extending into the lumen 
as a circular arc connecting adjacent struts.   
The following quantitative parameters were calculated for each stent (3):  
- Percentage of ISA:  calculated as a ratio of the total number of struts 
observed at 1 mm intervals. 
- Percentage of stents with ISA at the proximal and distal edges defined as the 
last 5mm of stent before the stent end.  
- ISA area, mm2 (only for BVS) measured as illustrated in Figure 1 . 
- Tissue prolapse area (mm2); calculated as the difference between the stent 
area and the lumen area as illustrated in Figure 1.  
- Percentage of RAS calculated as (1-[min lumen area/RVA])x100 as 
illustrated in Figure 2. 
- Eccentricity index: ratio between the minimal and the maximal diameter. For 
each stent both the mean and minimal eccentricity index were computed  
(illustrated in Figure 2). 
- Symmetry index: defined as (maximum stent diameter–minimum stent 
diameter)/(maximum stent diameter).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Qualitative and quantitative assessment of OCT characteristics 
A) Example of incomplete strut apposition. There are 4 malapposed struts between 10 and 12 o’clock in A1, with 
one more malapposed strut probably concealed by the wire shadow (asterix). In BVS the possibility to identify the 
abluminal border of the struts allow the evaluation of ISA area as indicated in green in panel A2. B) Tissue prolapse. 
In the presence of tissue prolapse, defined as tissue protruding between the struts, prolapse area was measured as the 
difference between  the stent and  lumen area (highlighted in green in Panel B2). C) Example of edge dissection 
(arrow) distally to the BVS. Because of the large lumen size and small circumferential extension of dissection no 
treatment was performed. D) BVS strut fracture. This cross section at the level of the LAD-D1 carina, shows a 
scaffold pattern irregularity with an overhanging strut (arrow) in the centre of the vessel without obvious connection 
to the expected/adjacent strut pattern.  In this patient before this final OCT acquisition the BVS was rewired in order 
to dilate the ostium of D1 with a 2.5 mm semicompliant balloon.  
 
 
 
Figure 2: Residual Area Stenosis and Eccentricity Index  
The proximal and distal vessel reference area (Panel A and D) were used to calculate the reference vessel area 
(RVA).  The ratio between minimal lumen area (MLA) and RVA was used to compute the residual area stenosis 
(Panel C). In Panel B is reported an example of evaluation of the minimum eccentricity index.  
 
 
 
 Follow-Up 
Clinical follow up was obtained approximately at 1 month after the procedure and 
every 6 months afterward by direct clinical examination.   
Statistical analysis 
Descriptive statistics (means and standard deviations for continuous variables with 
normal distribution, frequency and relative frequency for categorical variables) 
were computed according to treatment type (BVS vs DES). Comparison between 
groups for continuous variables was performed by unpaired T-test (in case of 
parametric distribution) or Mann-Whitney U-test (in case of non-parametric 
distribution), as appropriate. Univariate associations between treatment type and 
coronary lesion features were examined using two-way contingency tables. 
Significance of associations were assessed using the Chi-squared test or the Fisher 
exact test, as appropriate. For all the statistical tests used, a p level of <0.05 was 
required to reject the null hypothesis. The statistical analysis was performed using 
the SPSS statistical software package v 16.0 (IBM Corporation, Somers, NY). 
 
Results 
Population  
Fifty lesions treated with 63 BVS in 35 patients were matched with 50 lesions 
treated with 61 second generation DES in 38 patients.  Baseline patients’ clinical 
characteristics are shown in Table 1. There were no significant differences in the 
two groups with a minority of patients (4.1%) presenting with unstable angina as 
an indication for the PCI procedure.  
 
 
 
Table 1: Patients characteristics (n=73) 
 
 
 
Angiographic and QCA baseline lesion characteristics are summarized in Table 2. 
The left anterior descending (LAD) was the target vessel in a large proportion of 
cases in both groups (BVS n=34, 68%, DES n=25, 50%; p=0.11). As expected, 
based on the inclusion criteria, all lesions met the American College of 
Cardiology/American Heart Association classification criteria for B2 or C lesions. 
There were no significant differences in presence of calcification, ostial 
involvement and bifurcation involvement. Reference vessel diameter, minimal 
lumen diameter and lesion length, as assessed with QCA were also similar (lesion 
length: BVS 24.7±14.2mm, DES 25.1 ± 10.6mm; p=0.86).  Two CTO were 
successfully treated in the BVS-group and 4 in the DES-group. 
 
Table 2: Angiographic and QCA lesions characteristics  (n=100)   
 
 
 
Procedural characteristics 
Sixty-three BVS and 61 DES were implanted with a similar number of stent per 
lesion in the two groups (BVS 1.3±0.6, DES 1.2±0.5; p=0.28). 
Xience Prime was the most frequently used DES (n=35, 57.4%), while Promus 
Element or Premiere and Resolute Integrity were used in 16 (26.2%) and 10 
(16.4%) of cases, respectively. The mean stent length was 28.0mm [20.5-28.0] in 
the BVS-group and 28.0 [20.0-38.0] in the DES-group (p=0.42). As shown in 
Table 3, a higher balloon diameter/mean reference vessel diameter ratio was used 
for predilatation in the BVS group (BVS 1.1±0.1, DES 0.9±0.1; p<0.01) with 
significantly higher pressure inflation for both pre and post-dilatation. NC balloons 
were more frequently used for lesion preparation in the BVS group. Sequential 
dilatation was the only technique used for bifurcation optimization in BVS group 
while kissing balloon was consistently used in the DES group.  
 
Table 3: Procedural characteristics (n=100) 
 
 
Optical coherence tomography findings 
OCT findings are summarized in Table 4. A total of 2,953 cross-sections and 
24,352 struts were analyzed. Mean and minimal lumen area were similar in the two 
groups. The incidence of RAS>20% was not statistically significant different in the 
BVS (BVS: n=25, 39.7%, DES: n=26, 42.6%; p=0.85) and there was no difference 
in the mean RAS (BVS 20.2±7.5, DES 21.7%±9.9; p=0.32). There was a higher 
incidence of ISA at the proximal edge in the BVS group (BVS n=25, 39.7%, DES 
n=14, 23.0%;p=0.04) but no difference in the overall percentage of ISA (BVS 
1.7%±2.1, DES 1.9%±2.4; p=0.62) and number of stents with ISA (BVS n=33, 
52.4%, DES n=39, 63.9%; p=0.19) (see Figure 3). 
 
Figure 3: Histograms show a similar mean and minimal in stent  lumen area (A), percentage of residual area stenosis 
and stent with residual area stenosis > 20% (B), overall percentage of malapposed struts (C).  A higher incidence of 
proximal strut malapposition at the proximal edge was observed in BVS (D). 
 
 
The mean and minimum eccentricity index and the symmetry index were similar in 
the two groups. 
In the BVS group, there was a trend toward a higher prolapse area (BVS 
1.5±2.4mm2, DES 0.8±1.2mm2; p=0.08) but this did not significantly impact on 
the final lumen area, which was similar in both groups. OCT analysis showed 12 
edge dissections (BVS n=5, 7.9%, DES n=7, 11.5%; p=0.55) which were not 
apparent on the angiogram.  None of these required further stent implantation. In 
the DES group, strut fractures were not observed while in two patients in the BVS 
group two stent fractures developed.  In both cases the lesions were localized in the 
LAD across the origin of a diagonal branch and the scaffolds were recrossed in 
order optimize the result with sequential  dilatation . 
Table 4: Optical Coherence Tomography findings (n=124) 
 
 
Clinical follow up 
Clinical follow-up data were available for all BVS patients and for 31 (89.5%) 
patients in the DES group. The mean duration of follow up was significantly 
different in the two groups (BVS: 8.5±2.8 months; DES 17.3±8.7 months; p<0.01).  
One patient treated with two BVS in the proximal, mid and distal LAD presented 
two months later with ACS due to a critical lesion in a diagonal branch not treated 
with stenting during the index PCI, though the three  previously implanted BVS 
were patent.  One insulin-dependent diabetic patient with a proximal LAD BVS 
required coronary artery by-pass after 9 months because of diffuse distal disease 
progression (no in-stent restenosis).  In the DES group 2 patients (5.3%) underwent 
PCI due to in-stent restenosis at 14 and 24 months respectively after the baseline 
PCI. 
Discussion 
This is the first OCT study to compare acute stent performance between BVS and 
second generation DES in complex coronary artery lesions.  
The OCT indices used in our study are widely accepted as criteria for determining 
optimal stent deployment (45). These have been derived from IVUS criteria used 
for the evaluation of metallic stents and shown to correlate with 1-year clinical 
outcomes (stent thrombosis and restenosis) after implantation of BMS and first 
generation DES. In particular, a RAS of >20% and an absolute minimal cross-
sectional area <5.5 or 6.0 mm2 were previously correlated with acute/subacute 
stent thrombosis and restenosis (46). In our study, both the BVS and second 
generation DES mean RAS and absolute MLA were close to these cut-off levels. 
The thresholds defined in these early IVUS evaluations of DES were derived from 
analysis of trials including short type A-B1 lesions. Results on more complex 
lesions are limited and expected to be worse because of the higher plaque burden 
and resistance. In a previous study from our group calcified lesions with OCT were 
analyzed and a higher RAS and a greater ISA than in simple lesions was observed 
(47). The use of OCT rather than IVUS may explain part of the difference.  By 
virtue of its higher resolution, OCT can define more precisely the lumen area 
contours and quantify plaque prolapse, which is frequently concealed by strut 
artefacts when using IVUS. Moreover, OCT has been shown to measure lower 
absolute areas than IVUS, both in vitro and in vivo (48). The areas observed in the 
complex lesions of our BVS group were very similar to those reported in an OCT 
sub-study of the ABSORB trial cohort B in which relatively simple lesions were 
treated. Also the type of metallic stents used may play a role. The thick stainless 
steel struts of first generation DES may create a rough cobblestone surface at 
higher risk of thrombosis but have less recoil than the thin struts of second 
generation stents constructed using alloys such as cobalt or platinum chromium 
(49).   
The lack of difference between BVS and second generation DES in mean and 
minimal values of relative and absolute stent area, is the true novel finding of the 
current study. This could be expected based on in vitro studies conducted by the 
industry for registration and on small comparative studies with IVUS between 
BVS and Xience V stents. The observations made using OCT in the current study 
support the application of BVS beyond the current indications. These results 
suggest that a satisfactory BVS expansion can be achieved also in complex 
coronary lesions, at least when appropriate lesion preparation and deployment 
under OCT guidance is performed.  
The clinical relevance of ISA is controversial. Previous IVUS studies using first 
generation DES to treat simple lesions (50) showed no value in predicting late 
adverse events. However, an IVUS study performed at the time of acute stent 
thrombosis showed a higher incidence of ISA compared with controls (14). In our 
study, no difference was observed in the absolute number and percentage of 
malapposed struts between BVS and DES, with the latter being considerably lower 
than shown in previous OCT studies of predominantly first generation DES. 
Repeated OCT examinations in both groups, prompted additional dilatations at 
high pressure with properly sized balloons, probably explain the low prevalence of 
ISA in the complex lesions treated in this study.  Some malapposition was still 
observed, in pre- or post-stenotic ectasic  segments, in eccentric calcific lesions 
and at bifurcations though in many cases this was impossible to correct completely 
despite serial or kissing balloon dilatation (51). In the BVS group, we observed a 
more frequent malapposition at the proximal stent edge (39.7% of BVS vs 23.0% 
of DES, p 0.04), which may have procedural relevance as struts protruding into the 
lumen complicate the advancement of balloons or additional distal stents. The 
greater conformability of second generation DES compared to BVS may explain 
these findings because extreme attention was paid to post-dilatation with 
appropriately sized balloons which covered the proximal edge of the BVS, which 
is angiographically well visualised by the radiopaque platinum proximal marker. A 
potential advantage of the bioresorbable technology over metallic device is that 
any acute ISA resolves after the process of strut degradation has been completed, 
though this process may require up to 2 years time (52).  
Gomez-Lara et al, performed an OCT sub-study from the ABSORB trial Cohort B, 
in which only 3mm diameter BVS device were deployed. These investigators 
found a higher incidence of malapposed struts in vessels with a maximal diameter 
>3.3 mm (42). These data emphasize the importance of correct vessel size 
measurement in order to select the appropriate BVS diameter. Based on this 
observation we recommend over-sizing BVS up to 0.5mm above the smallest 
reference vessel diameter, which allows better adaptation especially in tapered 
vessels.  
The amount of tissue prolapse was slightly higher in BVS than DES. This may be 
explained by differences in stent design and the lower number of struts per cross-
section in BVS compared with second generation DES. In our population of stable 
lesions the greater plaque prolapse was not clinically relevant as it did not alter the 
final mean and minimal lumen area.  Moreover, the thicker struts of BVS mean 
that the prolapsed plaque is always surrounded by the stent struts with less 
herniation into the vessel lumen and a smoother surface compared with thinner 
strut DES (Figure 1). However, tissue prolapse is more prominent in unstable or 
thrombus containing lesions and in this setting the scaffolding properties of BVS 
might be insufficient to counteract plaque prolapse.    
A very similar post-procedural stent geometry was observed in both BVS and 
DES. Mean and minimum value of eccentricity index were similar in the two 
groups.   Brugaletta et al reported a higher symmetry index value for BVS while 
the eccentricity index was significantly lower in BVS compared to DES (0.85±0.08 
versus 0.90±0.06,  p<0.01).  In the current study, the minimal eccentricity index 
was lower for both BVS and DES in comparison to the findings from Brugaletta et 
al., likely a consequence of including more complex lesions. 
 
Limitations 
The favorable acute mechanical performance of BVS observed in this study cannot 
be given for granted unless implantation is performed with the same meticulous 
attention to lesion preparation, systematic sizing of BVS to the proximal reference 
vessel diameter and high pressure post-dilatation. Scaffold implantation has been 
performed under OCT guidance. Therefore, our results cannot be automatically 
applicable to conventional angiographic BVS deployment. The main limitation of 
this study is the use of a historical non randomized control group with a limited 
sample size and follow-up duration, which precludes any meaningful long-term 
clinical comparison of the rare long-term adverse events observed in patients 
treated with modern DES. Use of a matched cohort as a control population is 
frequently employed in the evaluation of novel devices and is certainly of value for 
the assessment of mechanistic response. There was no significant difference 
observed in key parameters of acute stent performance in the two subgroups 
treated with BVS or DES.  However, adjustments for multiple correlated 
observations were not performed and a definitive prove of non-inferiority would 
require a prospective randomized study with a larger study population. Prospective 
randomized controlled trials are required in order to determine whether the 
favorable acute mechanical performance of BVS observed in the current study can 
be translated into an improved long-term clinical outcome in patients with complex 
coronary lesions treated by PCI. The short follow-up duration provided in the BVS 
group may be inappropriate to observe disease progression and late target lesion 
failure.  Finally, although no new Q waves or ST elevation or prolonged chest pain 
were observed, we did not consistently measured post procedural troponin in all 
patients. 
 
 
 
 
 
 
 
 
 
 
 
2.1.5 Study 5 
Title: Very High Pressure Dilatation for Undilatable Coronary Lesions: 
Indications and Results with a New Dedicated Balloon 
 
Background 
The inability to fully dilate calcified lesion might result in an increased risk of stent 
restenosis and thrombosis. Increasing the pressure beyond the recommended limits 
during dilatation of resistant lesions often accentuates non-uniform balloon 
expansion with the consequent over-dilatation of the more compliant segments 
(dog-boning effect). Conventional non-compliant (NC) balloons have more 
predictable responses and uniform dilatation than semi-compliant balloons but the 
20 to 30 ATM limit that they reach can be insufficient. A variety of technologies 
such as rotational-atherectomy have been developed, however, the complexity and 
the cost of these devices have hindered their widespread use. 
 
Aim 
The aim of our study is to evaluate the safety and efficacy of a new dedicated 
super-high pressure NC-balloon (OPN, SIS Medical-AG, Winterthur-Switzerland). 
 
Materials and Methods 
Lesion Selection 
We evaluated 91 consecutive highly resistant coronary lesions in which 
conventional NC balloons failed to achieve an adequate post dilatation luminal 
gain. After the failed attempt with the plain NC balloon the OPN balloon was 
inflated up to 40 ATM. Other coronary lesions could be treated, when necessary. 
No exclusion criteria were applied. The OPN balloon is a CE mark device. Patients 
signed an informed consent for data treatment for scientific purposes and the study 
was conducted according to the Declaration of Helsinki. 
The OPN Balloon Device 
The OPN NC Super-High Pressure Balloon (SIS Medical AG, Winterthur 
Switzerland) is a rapid-exchange PTCA catheter compatible with 0.014” coronary 
wires. The most distinctive feature of the OPN balloon is the presence of a 
proprietary twin-layer balloon technology, which permits the use of very high-
pressure inflations and ensures uniform expansion over a wide range of pressures. 
The balloon is highly non compliant with a nominal pressure of 10 atm and a rated 
burst pressure of 35 atm. Each balloon is factory tested at 45 atm. The balloon 
diameters currently available cover a range from 1.5mm up to 4.0mm with ½ mm 
intervals. Lengths are 10, 15 and 20mm. The commercial name OPN comes from a 
sort of abbreviation of OP(E)N that in the company intention should sound 
commercially appealing for dilate a coronary stenosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Comparison between different  NC balloons compliance 3.0 mm diameter: Hiryu (Terumo Medical, 
Tokyo, Japan ), NC Quantum Apex (Boston Scientific, Natik, MA, USA), NC Sprinter RX (Medtronic, 
Minneapolis, MN, USA), Sapphire NC (OrbusNeich, Wanchai, Hong Kong), Empira NC (Cordis, Bridgewater, NJ, 
USA), OPN (Sis Medical, Winterthur, CH). Please note that the OPN NC balloon is the only one commercially 
available NC PTCA balloon catheter with a satisfactory compliance up to 35 ATM. 
 
 
 
Interventional Procedure 
The PCI was routinely performed with standard techniques via femoral or radial 
approach using 6 or 7 French guiding catheters. Patients not preloaded with oral 
aspirin and/or clopidogrel received a loading dose of intravenous aspirin (500mg) 
and clopidogrel (600mg) or prasugrel (60 mg) as standard practice in our 
Catheterization Laboratory. Intravenous heparin (70 UI/Kg body weight) was 
administered before the procedure with subsequent boluses aiming at achieving an 
activating ACT between 250 and 300sec. The use of GP IIb/IIIa inhibitors was 
minimized and left to operator’s discretion. In all cases lesion predilatation was 
performed with a low profile normal balloon slightly undersized according to 
conventional angiographic criteria. In case of incomplete balloon expansion with 
visible indentation at inflation pressures close to the rated burst pressure the lesion 
was approached using conventional NC balloon inflated at least at the rated burst 
pressure and often higher. If also this step failed to provide an adequate luminal 
gain because of residual underexpansion of the balloon, the OPN balloon (with the 
same diameter as the NC balloon) was inflated up to 40 ATM. All lesions were 
finally treated with DES optimized by NC-balloon inflation when needed. In case 
of stent underexpansion with residual stenosis >40% assessed by angiography, the 
OPN balloon (with the same diameter as the NC balloon used) was inflated up to 
40 ATM for stent optimization. 
Angiographic Analysis 
As routine in our Centre, standard image acquisition of the treated stenosis was 
performed using two or more angiographic projections after intracoronary 
nitroglycerine 100-200 mcg or isosorbide dinitrate 2-3 mg to provide maximum 
coronary dilation. We identified the projection where the lesion was better 
visualized and appeared more severe with no overlapping and minimal 
foreshortening. We filmed the lesion in this view during all balloon inflations and 
for final angiography. QCA was performed using a computer-based QCA system 
(Medis, Leiden, The Netherlands) with the dye-filled guiding catheter used for 
calibration. MLD and % DS were measured at baseline, after conventional NC 
balloon dilatation, and after OPN balloon dilatation. Interpolated reference 
diameter was considered as reference segment diameter. Lesion length was defined 
as the distance from the proximal to the distal shoulder of the lesion. Acute gain 
after conventional NC balloon was defined as MLD (mm) post NC conventional 
balloon – baseline MLD (mm). Acute gain after OPN NC balloon was defined as 
MLD post OPN balloon (mm) – baseline MLD (mm). Incremental gain after OPN 
NC balloon was defined as MLD post NC OPN balloon (mm) – MLD post 
conventional NC balloon (mm).  
Follow-Up 
Clinical events were evaluated post-procedure, during hospitalization and at 30 
days follow up. 
Definitions 
Angiographic success was defined as the achievement of residual angiographic 
stenosis < 30% assessed by visual estimation with TIMI 3 flow. Procedural success 
was defined as the achievement of angiographic success without any MACE 
defined as death, myocardial infarction and repeat revascularization (CABG or 
PTCA). Twelve-lead electrocardiograms were recorded before, immediately after 
the procedure and at hospital discharge. In-hospital MACE was defined as any 
MACE occurred during hospitalization for the index procedure.  Follow up MACE 
was defined as myocardial infarction, death or target lesion revascularization (any 
repeat PCI or CABG at the lesion site) occurred during the follow up period. Post 
procedural access site “bleeding” was defined according to TIMI criteria (53) and 
hematoma was defined as an arterial puncture site swelling > 5 cm. 
Statistical Analysis 
Continuous variables were expressed as mean + standard deviation, while 
categorical variables were presented as numbers with percentage. Continuous 
variables were compared using paired student’s t-test. Categorical variables were 
compared using chi-square test. A P value < 0.05 was considered statistically 
significant. 
 
Results 
Patients and lesion characteristics are shown in table 1 and 2 respectively. The 
average age was 69.4 + 9.5 years with a prevalence of male sex (80.2%) and 
standard distribution of risk factors (hypertension 82.4%, hypercholesterolemia 
69.2%, diabetes 46.1%, previous or current smoking 65.9%). Out of the 91 lesions, 
54 were heavily calcified or fibrotic lesions (59.3%) in previously untreated 
vessels and 7 were ISR (7.7%) in which conventional NC balloons did not expand 
during predilatation. In the remaining 30 cases the OPN balloons were used after 
stent deployment for stent optimization (33%). Procedural characteristics are 
shown in table 2. Predilatation using a semi compliant balloon was performed in 
all cases and was then followed by a successive dilatation using a conventional NC 
balloon sized according to conventional angiographic criteria and inflated up to the 
rated burst pressure or slightly higher. A total of 128 NC balloons were used (1.4 
per lesion).  In all cases the dilatation performed with the conventional NC balloon 
failed to achieve an adequate balloon expansion and luminal gain. After the failed 
attempt the OPN balloon with the same diameter of the conventional NC balloon 
was inflated up to 40 ATM. A total of 91 OPN balloons were used (1 per lesion). 
Angiographic success was achieved in 84 lesions (92.3%). In 3 severely calcified 
subocclusive stenoses (3.3%) the OPN balloon failed to cross while in 2 cases 
despite successful crossing the OPN failed to achieve an adequate luminal gain 
(2.2%). All 5 lesions were finally successfully treated with rotational atherectomy 
(5.5%). The remaining 2 cases were undilatable lesions in small and tortuous 
vessels for which both rotational atherectomy and excimer laser therapy were 
deemed not safe (2.2%). GpIIb/IIIa inhibitors were used in 6 patients (6.6%). 
 
 
 
 
 
 
 
 
Table 1: Baseline Patient Characteristics 
 
 
 
Table 2: Lesion and Procedural Characteristics 
 
 
Angiographic Results 
QCA analysis is shown in table 3. Both MLD and acute gain were significantly 
greater and % DS was significantly lower post OPN balloon inflation compared 
with post-plain NC balloon inflation (1.7 + 0.8mm vs 2.4 + 0.9mm, p < 0.001; 41.1 
+ 15.8% vs 20.2 + 14.9%, p < 0.001). These results were achieved with no increase 
in balloon size but with a higher inflation pressure (37.2 + 2.7 atm vs 21.4 + 2.8 
atm, p < 0.001).  
 
Table 3: QCA Analysis 
 
 
 
Procedural and Clinical Outcome 
Angiographic and technical success with OPN balloons was achieved in 84 lesions 
(92.3%). In the remaining 7 cases (7.7%), 5 lesions were successfully treated with 
rotational atherectomy (5.5%) while the remaining 2 cases were undilatable lesions 
for which both rotational atherectomy and excimer laser therapy were not 
attempted because of small vessel size and excessive tortuosity (2.2%). No 
coronary perforation or balloon rupture and ST change were reported after the 
procedure. No In-Hospital and 30 days MACE were reported. No major post 
procedural bleeding were reported. Hematoma of the access site occurred in 5 
patients treated by a transfemoral approach (5.5%). 
 
Figure 1: Decrease in % of diameter stenosis (DS) in calcific lesions (Group A), stent optimization (Group B) and 
in-stent restenosis (ISR) (Group C). The incremental gain offered by the OPN balloon was sufficient to achieve 
angiographic success in all the three subgroups (0.81 + 0.47 mm in Group A; 0.77 + 0.41 mm in Group B; 1.34 + 
0.31 mm in Group C). 
 
 
Discussion 
In our Registry we tested the safety and efficacy of the OPN super high-pressure 
balloon in a consecutive series of truly heavy resistant coronary stenosis non 
responsive to plain NC-balloon dilatation. With the OPN NC-balloon we were able 
to achieve a more then acceptable postdilatatation luminal gain in 92% of the cases 
without the need of additional expensive devices. 
The mechanical properties of the arterial wall are critically dependent on the 
thickness, distribution and characteristics of the intimal plaque (54). Thick 
neointimal hyperplasia and severe coronary calcification contribute to increase the 
hoop stress to the point that even high-pressure non-compliant balloons might be 
insufficient to overcome the hoop stress and induct a satisfactory dilatation.  
During dilatation of resistant coronary lesions the non-uniform balloon expansion 
with the consequent over-expansion of the more compliant segment (the so called 
“dog-boning” effect) may lead to an increased risk of vessel wall damage including 
edge dissections and coronary perforation. Varieties of devices and strategies have 
been developed to overcome this limitation. Cutting balloons have been designed 
to relieve the vessel hoop stress by creating controlled small incisions in the vessel 
wall and present the practical advantage that they do not move during inflation due 
to the stabilising effect of the blades. Cutting balloons present several advantages 
for the treatment of severe calcified lesions, allowing a larger luminal gain at lower 
pressure compared to balloon angioplasty alone and preventing the late recoil due 
to the incisions created by the blades (39). The lack of clinical benefit observed in 
the early studies of cutting balloon vs conventional balloon angioplasty in de novo 
lesions, have created scepticism on the potential mechanical usefulness offered by 
a focal concentration of force on the intimal plaque.  
Mehran et al (12) showed that when treating instent restenosis with balloon 
angioplasty, luminal gain is achieved by a combination of additional stent 
expansion and neointimal tissue compression through the stent resulting in a 
displacement through the stent struts and compression of neointimal tissue. 
Although satisfactory initial clinical and angiographic results were obtained with 
balloon angioplasty, a significant early lumen loss was also observed shortly after 
in-stent restenosis treatment due to recoil and re-intrusion of neointimal tissue in 
the lumen. This early phenomenon possibly influences the long-term outcome after 
balloon angioplasty for in-stent restenosis, affected by a high re-restenosis rate. 
Despite these findings, several randomized study showed no real advantage of CB 
over PTCA with conventional balloon and both the rigidity and the risk of balloon 
entrapment can limit their routinely use during treatment of heavily coronary 
lesions.  
Modification of the vessel wall using rotational atherectomy and excimer laser 
therapy improves vessel wall compliance thus facilitating uniform stent expansion.  
The Excimer laser therapy is based on the principle of photoablation converting 
occlusive material into microbubbles being immediately dissolved in the blood 
(55) and its use during treatment of resistant coronary lesions has been successfully 
described (56).  
Rotational atherectomy is a technique in which a small grinder is inserted into the 
coronary arteries to ablate the plaque. It is specifically effective in the treatment of 
calcified lesions because of its differential cutting mechanism, a phenomenon by 
which soft tissues (such as the normal arterial wall) are deflected so that the 
grinder will not contact them during high-speed rotation, while hard calcified 
plaques are not deflected and can be ablated by the grinder (57). Sizing-up the burr 
might enable better lesion modification, resulting in greater stent expansion and 
strut apposition. It is, however, unknown whether routine usage of aggressive 
rotational atherectomy is superior to conventional balloon dilatation as a means of 
lesion modification followed by DES implantation, because of the lack of systemic 
long-term results of such a strategy .  
Despite the majority of resistant coronary lesions can be treated with balloon 
dilatation and stent implantation alone, the rigid obstacle imposed by calcium or 
thick neointimal hyperplasia might prevent an optimal balloon expansion and 
symmetric stent deployment thus resulting in a gross malapposition of the stent 
struts. The importance of this is indirectly confirmed by findings from the e-
Cypher registry correlating calcific lesions with future occurrence of stent 
thrombosis (59). The real clinical consequence of strut malapposition is still matter 
of debate but surely may impinge on the elution properties of DES, increase the 
activation of fibrin and platelets, thus resulting in accelerated intimal hyperplasia 
or stent thrombosis. Although the use of dedicated devices such as rotational 
atherectomy might certainly improves procedural success during treatment of 
resistant coronary lesions both the complexity, the cost and the need of dedicated 
operators have hindered their widespread application.  
Conversely, the OPN NC Super-High Pressure Balloon is a plain rapid exchange 
PTCA catheter that can be easily attempted in case of failure of conventional 
balloons (60). Thanks to its twin-layer technology, it allows the use of very high-
pressure inflations ensuring uniform expansion over a wide range of pressures and 
reducing the risk of vessel damage (61). In our registry we found a significant 
increase of MLD and acute luminal gain after OPN balloon dilatation compared 
with plain NC balloon inflation. Moreover, as a consequence of the OPN uniform 
expansion we had no vessel rupture despite the use of very high-pressure 
inflations. In conclusion we believe that, when conventional NC balloon fail, OPN 
high-pressure balloons can provide an effective strategy for treatment of severe 
heavy coronary lesions. Moreover, this data suggest that the unique twin-layer 
technology offered by the OPN balloon achieves uniform balloon expansion 
reducing balloon rupture, vessel damage and coronary perforation. 
 
 
Figure 2: Angiographic and OCT images of an heavy calcific lesion pre-stenting (A), post a 3.0 x 18 ZES 
implantation followed by a NC balloon inflated at 22 ATM (B) and post dilatation with a 3.0 x 15mm OPN Balloon 
inflated at 38 ATM. Please note that the MLD increased to 2.92 mm (after the NC balloon dilatation) to 3.18mm 
(after the OPN dilatation).  In the IVUS/OCT guidance PCI of calcify lesion we found calcium around the vessel 
contour accounting for at least > 65% of the plaque, while OCT/IVUS imaging post OPN-dilatation shows diffuse 
vascular injuries following high-pressure inflation but without significant difference from the conventional NC-
balloon treated lesions. 
 
  
 
 
 
Limitations 
The main limitation of the OPN balloon is the high profile that, together with the 
stiffness of the twin-layer technology, in the vast majority of cases undermines any 
attempt to recross when inflated. The balloon does not refold well and after 
inflation is very difficult to use it again (for instance for both pre and postilatation). 
An independent core-lab and multiple observers QCA analysis would have 
improved reliability of data. Moreover our results come from a small sample-sized, 
retrospective and non-randomized comparison, which is certainly susceptible to 
selection bias.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2 OPTICAL COHERENCE TOMOGRAPHY DURING RENAL NERVE 
DENERVATION 
2.2.1 Study 6 
Title: Safety and efficacy of saline infusion for optical coherence tomography 
evaluation of vascular lesion induced by renal nerve ablation. 
 
Background 
Renal nerve ablation (RNA) using radiofrequency (RF) catheter-based has been 
recently proposed for the treatment of severe drug-resistant hypertension (62). 
Despite preliminary animal studies showed the safety and efficacy of this 
procedure, recent in-human studies highlighted the possibility of vascular lesions 
following RF emission. 
 
Aim 
For the first time ever our group evaluated the feasibility of OCT acquisition using 
selective saline infusion instead of contrast agent infusion. 
 
Materials and Methods 
After a renal denervation procedure we firstly performed a FD-OCT acquisition 
with a motorized pullback activated during injection of iodixanol 320 (Visipaque, 
GE Health Care, Cork, Ireland) via a 6 Fr guiding catheter at a flow rate sufficient 
to have full substitution of blood with contrast with no streaming according to the 
international guidelines developed for intracoronary imaging (3). Subsequently, we 
performed a further OCT acquisition in the same renal artery after a gentle and 
prolonged manual injection of 30 ml of saline. 
The two pull-backs were then compared, using the off-line LigthLab OCT imaging 
station, in order to evaluate the quality and the ability to detect vascular injuries in 
the saline-OCT acquisition. After proving the safety of saline intra-renal flush we 
evaluated so far 13 renal arteries. Of these, 12 were imaged before and after RDN-
procedure; in one case OCT was used during treatment of a renal in-stent 
thrombosis. In the first 4 arteries the quality of the cross sections obtained after 
saline infusion were compared with conventional OCT acquisition performed 
according with international guidelines developed for intracoronary imaging. To 
this, we firstly performed a FD-OCT acquisition with a motorized pull-back 
activated during injection of iodixanol 320 (Visipaque, GE Health Care, Cork, 
Ireland) via a 6 Fr guiding catheter at a flow rate sufficient to have full substitution 
of blood. Subsequently we performed further OCT acquisition after a gentle and 
prolonged manual injection of a 30ml of pure saline. The pull-backs were then 
compared. The remaining 9 arteries were imaged only after saline flush and in all 
cases OCT provides useful informations of the vessel wall angiographically silent. 
 
Results 
The standard OCT pull-backs using crystalloid infusion was certainly clearer 
especially at the center of the vessel lumen where the higher viscosity of 
crystalloid was able to achieve a greater blood clearance during imaging 
acquisition. Despite this, the subsequent saline-OCT acquisition achieves a 
sufficient quality to detect all vascular RF-induced lesions with accuracy equal to 
the crystalloid-OCT pull-back (Figure 1). 
 
 
 
 
 
 
 
 
  
Figure 1: A: OCT images acquired respectively after crystalloid infusion (A.1) and saline infusion (A.2). Please note 
that despite a clearer lumen obtained after crystalloid infusion both images clearly show the presence of a plaque 
located at the proximal segment of the renal artery (11 o'clock). B: OCT images acquired after crystalloid infusion 
(B.1) and saline flush (B.2) in a relatively healthy segment of the artery. C and D: OCT images obtained 
respectively after crystalloid (C) and saline infusion (D). Please note that both images are able to detect a local 
vascular injury at the RF-emission site (white arrow). 
 
 
 
 
 
 
Discussion 
Templin et al. recently evaluated 32 renal arteries before and after the RNA-
procedure using optical coherence tomography (OCT) (63). Thanks to its high 
resolution OCT was able to detect local vascular injuries angiographically silent. 
Lesions included prominent vessel notches at RF emission sites suggesting 
endothelial-intima edema, protruding masses attached to luminal surface 
suggesting thrombus and one vessel dissection. The real clinical impact of these 
findings is still unknown debating between the possibility of renal artery stenosis 
as an evolution of such injuries and no clinical sequelae (64). Notably, 
histopathological vascular analysis of renal arteries of swine which underwent 
renal nerve ablation did not show vascular lesions at 6 months follow-up despite 
diffuse injury of the vessel wall in the acute phase (65). Despite this, it is no doubt 
that creating a lesion into a relatively healthy vessel must be carefully evaluated in 
the long-term clinical follow-up. These data highlight the importance of a high-
resolution intravascular imaging technique during treatment of renal arteries. Ierna 
et al., using OCT after RNA, suggested the possibility of prolonged dual 
antiplatelet therapy in patients presenting renal vascular lesions including 
thrombus. Despite this, the routinely use of OCT for guidance of renal 
interventions is limited because of the need of prolonged crystalloid infusion 
during imaging. Frequency domain OCT (FD-OCT) has the advantage of a more 
rapid image acquisition due to the fast-scanning laser systems able to minimize the 
contrast use and to increase imaging speed while delivering comparable or 
improved image quality than with the earlier time domain systems. This allows 
multiple acquisitions of the entire segment of interest but still requires a selective 
renal injection of an amount of contrast medium greater than required for the 
control angiogram. Selective prolonged crystalloid infusion might be particularly 
deleterious in this subset of patients with resistant hypertension that are at 
potentially higher risk of poorer renal function. In fact, the main obstacle to the 
adoption of OCT imaging in clinical practice is that OCT cannot image through a 
blood field requiring clearing or flushing of blood from the lumen usually achieved 
by contrast agent infusion. However, thanks to the favorable blood kidney flow, 
saline itself might be sufficient to clear the blood from the vessel lumen for the 
entire acquisition period. To our best knowledge this is the first report describing 
the use of FD-OCT in RNA-procedure by using only saline flush and without the 
need of balloon occlusion or iodinated contrast medium infusion. We believe that 
this might improve the safety profile of this imaging technique enlarging the 
possibility of OCT evaluation of renal artery following renal nerve ablation in 
particular in patients with already advanced stages of renal insufficiency. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2.3 OPTICAL COHERENCE TOMOGRAPHY DURING PERIPHERAL 
VASCULAR INTERVENTION 
2.3.1 Study 7 
Title: Saline vs contrast infusion during optical coherence tomography 
imaging of peripheral percutaneous intervention 
 
Background 
Successful percutaneous revascularization of femoral and popliteal arteries 
dramatically differs from PCI because of the several mechanical stresses such as 
torsion, compression, flexion and extension induced by the large muscular groups 
(66).  
 
Aim 
We decided to test the feasibility of saline infusion during OCT evaluation of 
superficial femoral artery (SFA) atherectomy. 
 
Materials and Methods 
We performed a FD-OCT (St Jude, Minneapolis, MN, USA) acquisition after a 
gentle and prolonged manual injection of 50 ml of saline. The images were then 
compared with another OCT-guided SFA TurboHawk (Covidien, ev3 
Endovascular, Inc., Plymouth, MN) atherectomy in which the motorized pullback 
was activated during injection of iodixanol 320 (Visipaque, GE Health Care, Cork, 
Ireland) at a flow rate sufficient to have full substitution of blood with contrast 
with no streaming according with international guidelines developed for 
intracoronary imaging (3).  
Results 
Despite a certainly, improved OCT acquisition using contrast flush (Fig. 1), pure 
saline was able to achieve a sufficient quality cross-section images to characterize 
vessel injuries and increase in mean luminal area (MLA) following atherectomy 
(Fig. 2).  
 
Figure 1: Panel A and G shows angiography of a SFA pre and post rotational atherectomy. Panel B, C, D, E, F are 
OCT images acquired after infusion of pure contrast. Please note in panel B and D (*) the vessel dissection 
following plaque debulking that required prolonged balloon inflation. Notable the images are of high quality with a 
proper blood clearance due to the high viscosity of the crystalloid infusion. 
 
 
 
 
 
 
Figure 2: Panel A and G shows angiography of a SFA pre and post rotational atherectomy. Panel B, C, D, E, F are 
OCT images acquired after infusion of pure saline. Please note in panel D and F (*) the vessel dissection following 
plaque debulking that required prolonged balloon inflation. Despite a certainly worst blood cleareance especially at 
the center of the vessel lumen the images are of more than acceptable quality to detect vascular injuries following 
Turbohawk atherectomy. 
 
 
 
 
Finally, in order to stress the concept a same SFA was firstly OCT-imaged after 
contrast flush and after manual injection of 40 ml of Lactated Ringer's. In both 
pull-backs we were able to detect all vascular induced lesions as well as post 
atherectomy luminal gain with an equal accuracy (Fig. 3).  
 
 
Figure 3: OCT cross-sections acquired after contrast flush (A) and Lactated Ringer's infusion (B). Please note that 
both images equally provide adequate information of vessel injuries following TurboHawk atherectomy. 
 
 
 
 
In case of extremely large SFA and poor image quality we suggest a simultaneous 
manual compression of the common femoral artery as described by Karnabatidis et 
al. (67). However, from out of our initial experience of 12 SFA OCT-imaged using 
pure saline injections, in all cases we were able to achieve an acceptable image 
quality without the need of femoral artery compression that might theoretically 
cause acute thrombosis. 
 
 
Discussion 
Optical coherence tomography is a near-infrared light based technology that 
enables to provide cross sectional images with an axial resolution of up to 10–15 
µm resulting in a refined analysis of the vessel wall. The main reason why this 
technology is so infrequently used is both for the need of additional crystalloid 
infusion during imaging and for the low penetration power that is unable to deeply 
characterize the plaques. The introduction of the user friendly Frequency Domain 
system (FD-OCT) has partially overcome the limitations of the old Time Domain 
(TD-OCT). The fast-scanning laser system enables the TD-OCT to achieve images 
of longer segments (up to 54 mm) and larger arteries without the need of transient 
balloon occlusion, thus reducing the risk of vascular damage during imaging. 
However, OCT has been mainly evaluated during coronary intervention where its 
ability to disclose vessel microstructure might lose some of the clinical relevance. 
In fact, during percutaneous coronary intervention (PCI) the gold standard 
treatment sees, in the vast majority, the stent implantation as a final step 
irrespective of the plaque characterization and vessel wall injuries following lesion 
preparation. Successful percutaneous revascularization of femoral and popliteal 
arteries dramatically differs from PCI because of the several mechanical stresses 
such as torsion, compression, flexion and extension induced by the large muscular 
groups. These findings might explain the poor long-term outcome after peripheral 
percutaneous transluminal angioplasty (PTA) and the high rate of stent fractures at 
these sites (68). We believe that in this field, where the role of atherectomy and 
balloon angioplasty alone still plays a pivotal role, using an imaging modality able 
to precisely characterize the vessel all response to interventional devices might 
provide useful information. Despite this, the significant additional amount of 
contrast required for OCT evaluation of large muscular arteries might expose this 
population to an increased risk of nephropathy and unfortunately, peripheral artery 
disease especially affects a setting of patient with major concomitant comorbidities 
such as diabetes, hypertension, poor renal function and other cardiovascular 
disorders. Our group firstly described the safety and feasibility of OCT acquisition 
during imaging of vascular lesions induced by renal nerve radio- frequency (RF) 
ablation using selective saline infusion instead of contrast flush (69). By manually 
injecting 30 ml of pure saline solution we were able to achieve a sufficient 
substitution of blood enable to detect vessel RF-induced lesions as during 
iodixanol 320 (Visipaque, GE Health Care, Cork, Ireland) infusion. Following our 
first experience, we decided to test the feasibility of saline infusion during OCT 
evaluation of superficial femoral artery (SFA) atherectomy. We believe that our 
findings might enlarge the use of OCT guidance during peripheral artery 
interventions where the use of a stent to seal vessel trauma following balloon 
inflation or plaque atherectomy is not as obvious as during PCI and the response of 
the vessel wall, not always detectable by angiography alone, acquires an 
imperative role. 
 
 
 
 
 
 
 
 
 
 
 
2.3.2 Study 8 
Title: Optical Coherence Tomography guidance during peripheral vascular 
intervention. 
 
Background: 
The additional use of optical coherence tomography during peripheral 
percutaneous transluminal angioplasty (PTA) has been very few reported. We 
believe that, thanks to the extremely high resolution rate able to characterize vessel 
microstructure, might be an interesting, potential adjunctive tool during PTA 
where the use of a stent to seal vessel trauma following balloon inflation or plaque 
atherectomy its not as obvious as during coronary intervention. 
 
Aim 
We tested the safety and efficacy of OCT during peripheral percutaneous 
transluminal angioplasty. 
 
Materials and Methods 
During percutaneous transluminal angioplasty of lower limbs we performed 
additional FD-OCT (St Jude, Minneapolis, MN, USA) acquisition after a gentle 
and prolonged manual injection of 50 ml of saline or, in case of poor images 
quality and unacceptable results, contrast flush at a flow rate sufficient to have full 
substitution of blood with contrast with no streaming according with international 
guidelines developed for intracoronary imaging. Finally we evaluated the 
additional information provided by OCT pullbacks and how did it modify our 
procedures. 
 
Results 
The results can be reassumed as following: 
In the first figure we present both angiographic and OCT evaluation after 
TurboHawk (Covidien, ev3 endovascular, Inc., Plymouth, MN) atherectomy 
resulting in a proper luminal gain without excessive vessel trauma (Fig. 1). In this 
contest the patients did not require any additional treatment. 
Figure 1: OCT (A) and Angiogram (B) of a stenotic SFA pre-intervention and OCT (C) and Angiogram (D) of the 
same artery after successful atherectomy. 
 
 In contrast, the OCT evaluation of the second figure clearly shows a diffuse 
vascular trauma following the use of TurboHawk not detectable by angiography 
alone. In this case, we then decide to perform several additional balloon low-
pressure inflations resulting in reduction of vascular injuries as showed in the final 
OCT acquisition (Fig. 2). 
Figure 2: OCT (A) of a SFA after atherectomy; please note the diffuse vascular injuries following TurboHawk 
atherectomy not detectable by angiography alone (B). Panel C shows OCT image of the same artery with a visible 
reduction of the vessel injuries after several prolonged balloon inflation despite a superimposable angiogram (D). 
 
 
OCT acquisition of in the third figure shows a residual plaque burden despite first 
atherectomy not detectable by angiography alone. The patients underwent to 
further TurboHawk pass with a final acceptable luminal gain as clearly showed by 
final OCT images (Fig. 3). 
Figure 3: SFA OCT (A) and Angiogram (B) pre-intervention, post unsuccessful first atherectomy (C, D) and the 
final result (E, F) after a further TurboHawk debulking. Please note that despite an almost superimposable 
Angiogram (D, F), OCT images clearly shows a significant luminal gain achieved with the second step atherectomy 
(C, D). 
 
  
Discussion 
In the last decades angiography has been the keystone to asses vascular anatomy 
leading to a widespread development of percutaneous revascularization techniques 
both for coronary and peripheral vascular disease. Despite being a relatively low 
cost, high reproducible and safe technique, angiography alone can only provide a 
limited analysis of the lumen profile, without the possibility to disclose vessel wall 
characteristics and with a relatively low resolution rate compared with newer 
intravascular imaging techniques. Intravascular ultrasound (IVUS), firstly 
introduced in interventional cardiology in the early 90’s, has shown to be a 
valuable adjunctive tool even in the field of peripheral vascular interventions (70). 
Optical Coherence Tomography (OCT), a more recent, light-based technique is 
similar to IVUS providing information about intravascular anatomy that far 
exceeds the level of detail obtained from conventional angiography (71). The use 
of near-infrared light rather than ultrasound reflectance allows OCT to have higher 
spatial resolution (with up to 10 to 15 µm of spatial resolution compared with the 
100 to 200 µm resolution of IVUS) but lower penetration power (1 to 3 mm into 
vessel wall compared with the 4 to 10 mm of IVUS). Moreover, near-infrared light 
is scattered by red blood cells, therefore OCT use for guidance of intervention was 
limited by the need of prolonged  crystalloid infusion during imaging and OCT has 
been initially employed more as a research tool despite a real clinical adjunctive 
technique. The Frequency domain OCT system (FD-OCT) has the advantage of a 
more rapid image acquisition due to the fast-scanning laser systems able to 
minimise the contrast use and to increase imaging speed while delivering an 
improved image quality than with the earlier time domain systems (TD-OCT). 
Thus this allows multiple acquisitions of the entire segment of interest (up to 
54mm) with an amount of contrast only slightly greater than contrast required for 
the control angiogram. The use of OCT during percutaneous coronary intervention 
(PCI) has been widely described and despite initial skepticisms is finally finding its 
role in daily clinical practice. Despite OCT usage during peripheral vascular 
intervention has been very few reported (72), we believe that it might provide 
useful information implementing proper peripheral lower extremity interventions. 
In fact, successful revascularization of lower limbs by percutaneous transluminal 
angioplasty (PTA) dramatically differs from PCI. Coronary intervention sees the 
use of drug eluting stent (DES) as the gold standard, while drug eluting balloons 
(DEB), balloon angioplasty alone or plaque atherectomy are mainly reserved for 
particular cases such as instent restenosis (ISR) or as a first revascularization step 
that will be finally followed by stent implantation. Unlike coronary, femoral and 
popliteal arteries are ones of the most dynamic vessels of the body, exposed to 
several mechanical stresses such as torsion, compression, flexion and extension by 
large muscolar groups. Despite high procedural acute success rate, these might 
explain the poor long term outcome after PTA with or without stenting and the 
high percentage of stent fractures at these sites (68). Unlike balloons and stents that 
push the plaque into the vessel wall, the promise of atherectomy is to offer the 
possibility to debulk the plaque, limiting the elastic recoil. However, atherectomy 
might cause several vessel wall injuries, not detectable by angiography alone, that 
might result in increased inflammation, higher rates of distal embolization and 
poorer outcome at long-term follow-up. The lack of clinical benefit observed in the 
early studies of atherectomy vs conventional PTA and/or stenting have created 
skepticism on its potential mechanical advantage. These studies were performed 
without systematic IVUS and/or OCT guidance, not allowing the distinction 
between atherectomy with a proper plaque debulking and procedures followed by 
insufficient plaque removal and diffuse vascular injuries unlikely to respond better 
to PTA. In so forth we thought that OCT might be a valuable adjunctive tool 
during superficial femoral artery (SFA) atherectomy distinguishing “successfull” 
vs “unsuccessful” debulking despite a superimposable control angiogram.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4 OPTICAL COHERENCE TOMOGRAPHY DURING CAROTID 
ARTERY INTERVENTION 
2.4.1 Study 9 
Title: Carotid artery stenting (CAS): an update. Optical Coherence 
Tomography during CAS: interaction between stent design and 
atherosclerotic plaque. 
 
Aim 
Aim of our study was to define new indications for treatment and to provide new 
criteria for material choice during carotid endovascular procedures using Optical 
Coherence Tomography (OCT) examination. 
Materials and Methods 
Using FD-OCT we evaluated the impact of stent design on plaque prolapse and 
risk of stroke after carotid artery stenting (CAS). 
Three designs of carotid stents with distinctive features have been widely 
available: Open-Cell (OC), Closed-Cell (CC), hybrid-cell (HYB). 
Moreover, a novel carotid stent design has been recently developed, namely the 
double layer mesh stent. The design should allow for high flexibility to 
accommodate tortuous anatomy and at the same time convey scaffold properties 
for optimal plaque coverage. This technology is characterized by an internal 
micromesh layer for plaque coverage and an external self-expanding nitinol layer 
for scaffolding offering the flexibility that characterize open-cell design stents. 
Currently, the only CE marked and commercially available double layer mesh stent 
is illustrated in Figure 6. The device is compatible with a 0.014′′ guide wire and 7F 
guiding catheter or 6F long sheath. The cell size of the micromesh is extremely 
small (0.381 mm2) allowing for extensive plaque coverage. It remains to be 
demonstrated whether this interesting concept will translate into a reduction of 
neurologic events associated with CAS. 
 
Figure 1: The self-expanding double layer mesh carotid stent RoadSaver
TM 
(Terumo,Japan). 
 
 
 
 
 
 
 
 
Discussion and Results 
While in coronary interventions miniaturization and refinement of stent design has 
allowed the interventionalists to perform more complex procedures and to solve 
most of the limitations of stenting, in CAS little research and development efforts 
have been allocated to improve stent characteristics. Recently, it has been 
recognized that the stent itself may substantially add to embolic protection in CAS 
through adequate scaffolding of the plaque once the embolic protection device 
(EPD) has been removed. The ideal properties of a carotid stent are a well-
balanced mix of high flexibility and conformability, to accommodate tortuous 
anatomy, as well as high plaque coverage, to prevent late embolization of debris. 
Stents structure is characterized by sequential aligned annular rings interconnected 
by bridges and the design may be either open cell or closed cell, depending on the 
density of the bridges between the rings. Open cell design stents presents some of 
the segment free from the adjacent rings allowing greater adaptation to the vessel 
anatomy at the price of less plaque coverage and higher risk of tissue prolapse. 
Closed-cell design stents are characterized by higher density of bridge 
interconnection, which reduces their conformability and increases the probability 
of malapposition but at the same time offers great plaque coverage. A hybrid 
configuration with an open-cell design of the proximal and distal segments 
combined with closed-cell design of the central segments has been developed: the 
hybrid stent design. 
The impact of stent design on clinical outcome following CAS has not been 
adequately addressed. An observational study found a significant lower rate of 
post-procedural events in patients undergoing closed-cell design stent implantation 
compared with individual allocated to open-cell design stenting, but these results 
were not confirmed by other registries showing poor correlation between in-
hospital and 30 days mortality and stent design (73-76). A nice insight in the 
impact of stent design and in the pathophysiology at the lesion level at the time of  
CAS comes from a prospective single-centre study enrolling 40 consecutive 
patients and designed to evaluate the rate of stent malapposition, plaque prolapse, 
and thin cap fibro-atheroma rupture according to stent configuration by optical 
coherence tomography (OCT) (Figure 4) (77). Closed-cell design stents were used 
in 17 patients (42.5%), open-cell design stents in 13 patients (32.5%), and hybrid 
design stents in 10 patients (25%). No neurological complications occurred. On 
OCT analysis, the frequencies of malapposed struts were higher with closed-cell 
compared with open-cell and hybrid design stents (34.5 vs. 15% and 16.3%, 
respectively; P < 0.01). Plaque prolapse was more frequent with open cell than 
closed cell (68.6 vs. 23.3%; P <0.01) and hybrid stents (30.8%; P <0.01). 
Significant differences were also noted in the rates of fibrous cap rupture between 
closed- and open cell (24.2 vs. 43.8%; P < 0.01), and between closed-cell and 
hybrid design (39.6%; P < 0.01) stents, but not between open-cell and hybrid 
design stents (P = 0.4). The authors concluded that micro-defects after stent 
deployment in CAS are frequent and are related to the design of implanted stents. 
While stent malapposition was more common following closed-cell design stent 
implantation, plaque prolapse was more common in patients treated with open- cell 
design devices. While these results are important, a correlation to clinical events 
remains to be demonstrated. 
The mechanism of delayed cerebral embolization following CAS is unknown but 
may include tissue prolapsed through the stent struts and thrombus formation 
around malapposed stent struts. Despite the fact that current guidelines recommend 
carotid artery revascularization exclusively on the basis of stenosis severity, the 
importance of plaque characterization in stratifying stroke risk has been 
increasingly recognized. The weak correlation between the severity of stenosis and 
the risk of stroke in asymptomatic patients found in several trials together with 
recently published data that link complex plaques with stroke challenge the ‘degree 
of stenosis-stroke risk’ paradigm, highlight the importance of the morphology and 
composition of the carotid plaques beyond the degree of stenosis and of the 
investigation of the complex stent – plaque interaction after CAS (78, 79). In this 
respect, calcified lesions may favour stent malapposition while soft plaques may 
result in greater tissue prolapse though the stent struts.  
Figure 2: Optical coherence tomography findings inside an open-cell carotid stent. (A) Malapposition of the stent to 
the vessel wall (B) intra-strut plaque prolapse (arrows). 
 
 
 
 
A promising help comes from a new double layer mash (DLM) stent design. The 
DLM stent present an internal micromesh layer for plaque coverage and an 
external nitinol layer that offers a flexibility of an OC stent. In our limited series of 
11 patients treated with the Roadsaver stent we found a great coverage of plaque 
coverage with no embolic events both at acute and long-term follow up. 
Figure 3: Optical coherence tomography assessment of a RoadSaver TM  stent showing no significant prolapse of 
plaque and good wall apposition. 
 
3. CONCLUSION 
With the increased diffusion of OCT, much has been documented in terms of its 
safety profile. 
First generation OCT systems required the use of an occlusion balloon situated in 
the proximal segment of the vessel inflated simultaneously during flush of Ringer’s 
lactate. Refinement of the technology, with faster acquisition speeds, has seen a 
gradual shift from the cumbersome occlusive technique to a simpler and safer non-
occlusive technique with flushing of viscous contrast through the guiding catheters 
(80). This technique has the advantages of shorter OCT procedure, larger amount 
of information with longer pull-back distance and evaluation of most proximal 
coronary segments with less patient discomfort. 
The need of blood clearance during imaging requires additional contrast agent 
infusion and might increase the risk of contrast-induced nephropathy and elicits 
transient chest pain and ECG change, which almost always resolve immediately 
following imaging.  
For one of the first time ever our group reported the safety and efficacy of saline 
infusion instead of contrast flush during FD-OCT acquisition. Certainly, this can 
be used only during peripheral intervention and is not suitable during coronary 
imaging because of the possible increased risk of ventricular fibrillation during 
injection of a significant amount of saline in the coronary artery. However, this 
finding might further enlarge the use of OCT during percutaneous peripheral 
approach.  
When first confronted with OCT of coronary artery, one cannot help be impressed 
by the clarity of the images. The understanding of OCT imaging, however, lies 
deep beyond this cursory assessment and requires appropriate interpretation. This 
remains one of the most painstaking aspects of off-line image interpretation.  
Much of what is currently known regarding stent safety has mainly arisen based on 
old studies using angiographic follow-up or IVUS in addition to invaluable 
information gained during the unlikely post-mortem setting. OCT has now become 
integral to a number of multi-center trials evaluating new generation drug eluting 
stent (DES) and bioresorbable vascular scaffold (BVS). Unlike conventional stents 
that develop circumferential coverage with an average thickness of 500 µm or 
more, which are well-visualized with IVUS and angiography (1-mm late loss), 
DES delay and prevent the hyperplastic response so that the average late lumen 
loss for -limus or paclitaxel-eluting stents can be lower than 100 µm. Therefore, 
the amount of intimal thickening will not be detectable with IVUS because of its 
limited axial resolution and the presence of artifacts around struts (15). The 
introduction of OCT, an imaging technique that employs near-infrared light and 
provides cross-sectional images with an axial resolution of 10 µm (16), has 
provided new opportunities to perform a more refined analysis of vessel response 
to endovascular devices offering a unique combination of minimally invasive 
surface scanning technology and in-vivo images of biological samples at a 
resolution 10–30 times higher than conventional IVUS. In fact several 
experimental and clinical studies demonstrated the high correlation between OCT 
and histological measurements of neointimal coverage of stent struts, highlighting 
the superiority of OCT over IVUS for in-vivo detection of stent tissue coverage at 
follow-up. 
OCT can be also used to guide optimal stent expansion and apposition especially 
during new thin strut DES and BVS implantation. Indeed, stent expansion, 
apposition and symmetry were the principal IVUS criteria in the bare metal stent 
era. Since infra-red light is unable to penetrate through metal struts, OCT 
visualizes only the endo-luminal surface of the strut and its thickness, combined 
with the one of the polymer should be considered during OCT DES evaluation. In 
addition to stent tissue coverage and apposition, OCT can be a complementary 
imaging modality when evaluating stent fracture, in cases of very late stent 
thrombosis and almost unique when examining absorption of the new 
biodegradable vascular scaffolds thereby yielding unique ante-mortem 
information. 
Few studies investigated the role of OCT guidance to lesion treatment. Our group 
showed in a single center series of 398 pull backs before and after stent 
implantation that 19% of cases were deferred according to the results of pre-
treatment OCT pullback and 33.8% of lesions after angiographic stent optimisation 
with high pressure balloon required additional expansion or stenting at the edges. 
In a series of 670 patients the outcomes of an angiographic guided strategy were 
compared with an OCT guided strategy. At one year follow up, the group treated 
with OCT had a lower rate of cardiac death and re-intervention (81). According to 
these early results, OCT seems to be, at least, as beneficial as IVUS for guidance 
of coronary interventions with the potential great advantage of immediate 
automated quantification of stent apposition and expansion. 
Finally, our group focused in a peculiar, poorly explored field: the use of OCT 
during non-coronary interventions. OCT confirmed its safety profile and provided 
unique clinically oriented informations that strongly encourage its use in this 
clinical “scenario”.  
Although the OCT is only recently entered in our catheterization laboratories, the 
promising results showed in this thesis support its usefulness in a wide range of 
clinical and research settings. 
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